CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | antidyskinesia agent |
|
Accession: | CHEBI:66956
|
browse the term
|
Definition: | Any compound which can be used to treat or alleviate the symptoms of dyskinesia. |
Synonyms: | related_synonym: | antidyskinesia agents; antidyskinesia drug; antidyskinesia drugs; antidyskinetic agent; antidyskinetic agents; antidyskinetic drug; antidyskinetic drugs |
|
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions affects localization |
ISO |
A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein] |
CTD |
PMID:15985612 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
[Fluoxetine co-treated with Amantadine] results in increased expression of BDNF mRNA |
CTD |
PMID:19211973 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Ifi27 |
interferon, alpha-inducible protein 27 |
increases expression |
ISO |
Amantadine results in increased expression of IFI27 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294
|
|
G |
Ifnar1 |
interferon alpha and beta receptor subunit 1 |
affects expression |
ISO |
Amantadine affects the expression of IFNAR1 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr11:30,725,774...30,752,227
Ensembl chr11:30,725,790...30,749,979
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
Amantadine results in increased expression of JAK1 protein |
CTD |
PMID:16756086 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Amantadine results in decreased activity of KCNH2 protein |
CTD |
PMID:21158687 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Map2 |
microtubule-associated protein 2 |
decreases expression |
ISO |
Amantadine results in decreased expression of MAP2 mRNA |
CTD |
PMID:34748853 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Oas2 |
2'-5' oligoadenylate synthetase 2 |
increases expression |
ISO |
Amantadine results in increased expression of OAS2 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Amantadine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Amantadine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
[Amantadine co-treated with Ursodeoxycholic Acid co-treated with 7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester] results in increased activity of STAT1 |
CTD |
PMID:15918519 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Tdp1 |
tyrosyl-DNA phosphodiesterase 1 |
decreases activity |
ISO |
Amantadine analog results in decreased activity of TDP1 protein |
CTD |
PMID:29248742 |
|
NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021
|
|
|
G |
Amy2a3 |
amylase 2a3 |
multiple interactions |
EXP |
Apomorphine results in increased secretion of and results in increased activity of AMY1A protein; Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Metoclopramide inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein] |
CTD |
PMID:21173550 |
|
NCBI chr 2:201,317,916...201,326,487
Ensembl chr 2:201,317,920...201,326,532
|
|
G |
Avp |
arginine vasopressin |
increases expression multiple interactions |
ISO |
Apomorphine results in increased expression of AVP protein Metoclopramide inhibits the reaction [Apomorphine results in increased expression of AVP protein] |
CTD |
PMID:16575035 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form] |
CTD |
PMID:25633564 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
decreases expression |
ISO |
Apomorphine results in decreased expression of BMPR1A mRNA |
CTD |
PMID:25633564 |
|
NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616
|
|
G |
Cck |
cholecystokinin |
multiple interactions decreases activity |
EXP |
Naloxone inhibits the reaction [CCK protein results in decreased activity of Apomorphine] |
CTD |
PMID:3561887 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Cckbr |
cholecystokinin B receptor |
affects response to substance |
ISO |
CCKBR protein affects the susceptibility to Apomorphine |
CTD |
PMID:11702094 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Apomorphine results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
ISO |
Apomorphine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Apomorphine results in increased activity of DRD1 protein] [[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] |
CTD |
PMID:8103921 PMID:15985612 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions affects response to substance increases response to substance |
ISO EXP |
[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein] DRD2 protein affects the susceptibility to Apomorphine DRD2 protein results in increased susceptibility to Apomorphine |
CTD |
PMID:2571179 PMID:7520908 PMID:8103596 PMID:8103921 PMID:14639100 PMID:19497322 More...
|
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
increases response to substance |
ISO |
DRD3 protein results in increased susceptibility to Apomorphine |
CTD |
PMID:19497322 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Apomorphine results in increased expression of FOS protein |
CTD |
PMID:10904129 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases expression |
ISO |
Apomorphine results in decreased expression of FURIN mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions |
EXP |
GDNF protein affects the susceptibility to [Apomorphine co-treated with Oxidopamine] |
CTD |
PMID:11771942 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gh1 |
growth hormone 1 |
increases secretion increases expression |
ISO |
Apomorphine results in increased secretion of GH1 protein Apomorphine results in increased expression of GH1 protein |
CTD |
PMID:993808 PMID:8889285 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
multiple interactions decreases secretion decreases expression |
ISO |
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] Apomorphine results in decreased secretion of HAMP protein modified form Apomorphine results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine] |
CTD |
PMID:8539317 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr6 |
5-hydroxytryptamine receptor 6 |
increases response to substance multiple interactions |
EXP |
HTR6 protein results in increased susceptibility to Apomorphine Ro4368554 inhibits the reaction [HTR6 protein results in increased susceptibility to Apomorphine] |
CTD |
PMID:17920665 |
|
NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein] |
CTD |
PMID:14599342 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases activity |
ISO |
Apomorphine results in increased activity of ODC1 protein |
CTD |
PMID:10354516 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Apomorphine inhibits the reaction [Reserpine results in increased expression of PENK mRNA] |
CTD |
PMID:17719177 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Prl |
prolactin |
decreases expression |
ISO |
Apomorphine results in decreased expression of PRL protein |
CTD |
PMID:8889285 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Pvalb |
parvalbumin |
affects expression |
EXP |
Apomorphine affects the expression of PVALB protein |
CTD |
PMID:15238432 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Rgs9 |
regulator of G-protein signaling 9 |
affects response to substance |
ISO |
RGS9 affects the susceptibility to Apomorphine |
CTD |
PMID:15728856 |
|
NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
EXP |
SHH protein modified form affects the susceptibility to [Apomorphine co-treated with Oxidopamine] |
CTD |
PMID:11771942 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Apomorphine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Sst |
somatostatin |
affects secretion |
EXP |
Apomorphine affects the secretion of SST protein |
CTD |
PMID:17961553 |
|
NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Syt7 |
synaptotagmin 7 |
multiple interactions |
EXP |
[Reserpine co-treated with Apomorphine] results in increased expression of SYT7 mRNA |
CTD |
PMID:17719177 |
|
NCBI chr 1:207,031,359...207,093,787
Ensembl chr 1:207,031,592...207,089,026
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Apomorphine promotes the reaction [Reserpine results in increased expression of TAC1 mRNA] |
CTD |
PMID:17719177 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO EXP |
COMT protein results in increased methylation of Benserazide |
CTD |
PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
ISO |
Benserazide binds to and results in decreased activity of DDC protein |
CTD |
PMID:35151785 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
[Oxidopamine co-treated with levodopa methyl ester] promotes the reaction [Benserazide results in increased expression of DRD1 protein] |
CTD |
PMID:19399396 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
[Oxidopamine co-treated with levodopa methyl ester] inhibits the reaction [Benserazide results in increased expression of DRD2 protein] |
CTD |
PMID:19399396 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Benztropine results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
increases expression |
ISO |
Benztropine results in increased expression of ACOT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Actbl2 |
actin, beta-like 2 |
increases expression |
ISO |
Benztropine results in increased expression of ACTBL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:42,858,020...42,860,767
Ensembl chr 2:42,858,020...42,860,767
|
|
G |
Actr1a |
actin related protein 1A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of ACTR1A protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:245,237,821...245,256,618
Ensembl chr 1:245,237,826...245,256,495
|
|
G |
Actr3 |
actin related protein 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of ACTR3 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Adsl |
adenylosuccinate lyase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of ADSL protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760
|
|
G |
Agps |
alkylglycerone phosphate synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of AGPS protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:60,747,323...60,845,831
Ensembl chr 3:60,747,323...60,845,830
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of AK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of ANXA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Benztropine results in decreased expression of ANXA5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Anxa6 |
annexin A6 |
decreases expression |
ISO |
Benztropine results in decreased expression of ANXA6 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:39,101,395...39,156,483
Ensembl chr10:39,097,109...39,156,433
|
|
G |
Anxa7 |
annexin A7 |
increases expression |
ISO |
Benztropine results in increased expression of ANXA7 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:3,821,798...3,849,659
Ensembl chr15:3,821,845...3,849,385
|
|
G |
Armt1 |
acidic residue methyltransferase 1 |
increases expression |
ISO |
Benztropine results in increased expression of ARMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:40,894,558...40,918,302
Ensembl chr 1:40,894,550...40,918,302
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Benztropine results in decreased expression of ASNS protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Asph |
aspartate-beta-hydroxylase |
increases expression |
ISO |
Benztropine results in increased expression of ASPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
increases expression |
ISO |
Benztropine results in increased expression of ATP2A3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of ATP5F1C protein |
CTD |
PMID:34122009 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
Benztropine results in decreased expression of ATP6V1B2 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Atxn10 |
ataxin 10 |
increases expression |
ISO |
Benztropine results in increased expression of ATXN10 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:116,441,768...116,565,093
Ensembl chr 7:116,441,613...116,565,087
|
|
G |
Baz1b |
bromodomain adjacent to zinc finger domain, 1B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of BAZ1B protein |
CTD |
PMID:34122009 |
|
NCBI chr12:21,431,985...21,489,956
Ensembl chr12:21,431,985...21,490,426
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
decreases expression |
ISO |
Benztropine results in decreased expression of BCAR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bltp1 |
bridge-like lipid transfer protein family member 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of BLTP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:119,708,114...119,924,697
Ensembl chr 2:119,708,209...119,924,695
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Benztropine results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brd2 |
bromodomain containing 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of BRD2 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:4,727,078...4,735,389
Ensembl chr20:4,728,151...4,735,388
|
|
G |
Bsg |
basigin |
decreases expression |
ISO |
Benztropine results in decreased expression of BSG protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression multiple interactions |
ISO |
Benztropine results in decreased expression of CALD1 protein [Cuprizone co-treated with Benztropine] results in decreased expression of CALD1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Calu |
calumenin |
decreases expression |
ISO |
Benztropine results in decreased expression of CALU protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of CAMK2D protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CAPRIN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502
|
|
G |
Casp8ap2 |
caspase 8 associated protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CASP8AP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:47,014,501...47,052,276
Ensembl chr 5:47,014,667...47,052,275
|
|
G |
Cbx5 |
chromobox 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of CBX5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Benztropine results in increased expression of CCAR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccdc121 |
coiled-coil domain containing 121 |
increases expression |
ISO |
Benztropine results in increased expression of CCDC121 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:24,970,845...24,973,451
Ensembl chr 6:24,970,833...24,973,478
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CCT6A protein |
CTD |
PMID:34122009 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cct7 |
chaperonin containing TCP1 subunit 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of CCT7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CCT8 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cd276 |
Cd276 molecule |
decreases expression |
ISO |
Benztropine results in decreased expression of CD276 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:58,937,751...58,968,082
Ensembl chr 8:58,937,751...58,968,380
|
|
G |
Cenpv |
centromere protein V |
increases expression |
ISO |
Benztropine results in increased expression of CENPV protein |
CTD |
PMID:34122009 |
|
NCBI chr10:47,214,479...47,228,552
Ensembl chr10:47,214,490...47,228,761
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
decreases expression |
ISO |
Benztropine results in decreased expression of CHD4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:157,898,503...157,931,632
Ensembl chr 4:157,899,391...157,931,541
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of CKB protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CNP protein Benztropine results in decreased expression of CNP protein |
CTD |
PMID:34122009 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of COL14A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of COL5A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
decreases expression |
ISO |
Benztropine results in decreased expression of COPS4 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:9,078,579...9,108,788
Ensembl chr14:9,078,576...9,108,887
|
|
G |
Coro1b |
coronin 1B |
decreases expression |
ISO |
Benztropine results in decreased expression of CORO1B protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:201,442,977...201,448,416
Ensembl chr 1:201,443,014...201,448,416
|
|
G |
Coro7 |
coronin 7 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CORO7 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:10,880,299...10,941,001
Ensembl chr10:10,885,196...10,941,001
|
|
G |
Cpne3 |
copine 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of CPNE3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:33,014,658...33,063,934
Ensembl chr 5:33,016,307...33,063,934
|
|
G |
Cpsf3 |
cleavage and polyadenylation specific factor 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CPSF3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:40,836,121...40,864,129
Ensembl chr 6:40,836,097...40,864,128
|
|
G |
Crtap |
cartilage associated protein |
increases expression |
ISO |
Benztropine results in increased expression of CRTAP protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Cryz |
crystallin zeta |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CRYZ protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Csde1 |
cold shock domain containing E1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CSDE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:190,546,015...190,582,787
Ensembl chr 2:190,554,980...190,582,784
|
|
G |
Cstf2 |
cleavage stimulation factor subunit 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of CSTF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:97,253,559...97,279,476
Ensembl chr X:97,253,586...97,279,476
|
|
G |
Ctbp1 |
C-terminal binding protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CTBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:77,455,580...77,482,821
Ensembl chr14:77,455,696...77,482,821
|
|
G |
Cul2 |
cullin 2 |
increases expression |
ISO |
Benztropine results in increased expression of CUL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:54,169,093...54,210,197
Ensembl chr17:54,169,086...54,209,968
|
|
G |
Cul4b |
cullin 4B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of CUL4B protein |
CTD |
PMID:34122009 |
|
NCBI chr X:117,287,481...117,326,688
Ensembl chr X:117,287,484...117,326,688
|
|
G |
Dars2 |
aspartyl-tRNA synthetase 2 (mitochondrial) |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of DARS2 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:73,308,726...73,336,558
Ensembl chr13:73,308,726...73,336,934
|
|
G |
Dazap1 |
DAZ associated protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of DAZAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:9,423,673...9,448,116
Ensembl chr 7:9,424,178...9,538,818
|
|
G |
Dctn2 |
dynactin subunit 2 |
increases expression |
ISO |
Benztropine results in increased expression of DCTN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Ddx17 |
DEAD-box helicase 17 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DDX17 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:111,091,127...111,109,353
Ensembl chr 7:111,089,445...111,109,193
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DDX3X protein |
CTD |
PMID:34122009 |
|
NCBI chr X:9,479,532...9,493,169
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Dgcr6 |
DiGeorge syndrome critical region gene 6 |
decreases expression |
ISO |
Benztropine results in decreased expression of DGCR6 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:82,927,725...82,932,823
Ensembl chr11:82,927,725...82,932,823
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
Benztropine results in increased expression of DHCR24 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhx8 |
DEAH-box helicase 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DHX8 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:86,667,641...86,704,198
Ensembl chr10:86,667,834...86,705,137
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DLAT protein Benztropine results in increased expression of DLAT protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
|
|
G |
Dlg2 |
discs large MAGUK scaffold protein 2 |
increases expression |
ISO |
Benztropine results in increased expression of DLG2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
increases expression |
ISO |
Benztropine results in increased expression of DNAJB11 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dpp3 |
dipeptidylpeptidase 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of DPP3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:202,204,683...202,228,501
Ensembl chr 1:202,204,693...202,228,541
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of DPYSL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dpysl3 |
dihydropyrimidinase-like 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of DPYSL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:35,374,427...35,480,228
Ensembl chr18:35,377,181...35,480,157
|
|
G |
Dync1li1 |
dynein cytoplasmic 1 light intermediate chain 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of DYNC1LI1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934
|
|
G |
Ebna1bp2 |
EBNA1 binding protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EBNA1BP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:132,148,164...132,152,730
Ensembl chr 5:132,148,143...132,153,267
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EEF1G protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Eif2s3 |
eukaryotic translation initiation factor 2 subunit gamma |
increases expression |
ISO |
Benztropine results in increased expression of EIF2S3 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:58,916,513...58,939,923
Ensembl chr X:58,917,490...58,940,686
|
|
G |
Eif3b |
eukaryotic translation initiation factor 3, subunit B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EIF3B protein |
CTD |
PMID:34122009 |
|
NCBI chr12:14,196,403...14,220,865
Ensembl chr12:14,196,403...14,220,886
|
|
G |
Eif3c |
eukaryotic translation initiation factor 3, subunit C |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EIF3C protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:181,134,604...181,152,489
Ensembl chr 1:181,134,604...181,152,493
|
|
G |
Eif3h |
eukaryotic translation initiation factor 3, subunit H |
decreases expression |
ISO |
Benztropine results in decreased expression of EIF3H protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:83,091,037...83,174,451
Ensembl chr 7:83,091,039...83,174,451
|
|
G |
Eif3l |
eukaryotic translation initiation factor 3, subunit L |
increases expression multiple interactions |
ISO |
Benztropine results in increased expression of EIF3L protein [Cuprizone co-treated with Benztropine] results in decreased expression of EIF3L protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:110,652,565...110,663,614
Ensembl chr 7:110,627,107...110,663,614
|
|
G |
Eif5 |
eukaryotic translation initiation factor 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EIF5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:130,589,162...130,597,656
Ensembl chr 6:130,589,143...130,597,656
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EIF5B protein Benztropine results in increased expression of EIF5B protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
|
|
G |
Eif6 |
eukaryotic translation initiation factor 6 |
decreases expression |
ISO |
Benztropine results in decreased expression of EIF6 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:144,325,038...144,331,396
Ensembl chr 3:144,325,036...144,331,401
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of ENO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Ephb3 |
Eph receptor B3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EPHB3 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:79,840,668...79,859,345
Ensembl chr11:79,840,668...79,859,370
|
|
G |
Epn1 |
Epsin 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of EPN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:68,742,491...68,760,570
Ensembl chr 1:68,742,789...68,758,874
|
|
G |
Eps8 |
EGFR pathway substrate 8, signaling adaptor |
decreases expression |
ISO |
Benztropine results in decreased expression of EPS8 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873
|
|
G |
Erh |
ERH, mRNA splicing and mitosis factor |
increases expression |
ISO |
Benztropine results in increased expression of ERH protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:100,280,933...100,291,200
Ensembl chr 6:100,280,930...100,291,210
|
|
G |
Erlin2 |
ER lipid raft associated 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of ERLIN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:65,017,654...65,034,184
Ensembl chr16:65,018,532...65,033,671
|
|
G |
Ewsr1 |
EWS RNA-binding protein 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of EWSR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544
|
|
G |
Exosc9 |
exosome component 9 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of EXOSC9 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:119,416,028...119,426,981
Ensembl chr 2:119,388,715...119,427,051
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
Benztropine results in decreased expression of EZR protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
ISO |
Benztropine results in increased expression of FABP3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of FDPS protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Flot2 |
flotillin 2 |
increases expression |
ISO |
Benztropine results in increased expression of FLOT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:62,926,047...62,947,759
Ensembl chr10:62,920,665...62,947,756
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of FLT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fyco1 |
FYVE and coiled-coil domain autophagy adaptor 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of FYCO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021
|
|
G |
G3bp2 |
G3BP stress granule assembly factor 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of G3BP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:15,932,403...16,020,555
Ensembl chr14:15,987,417...16,020,548
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases expression |
ISO |
Benztropine results in decreased expression of G6PD protein |
CTD |
PMID:34122009 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of GALNT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
|
|
G |
Gart |
phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GART protein |
CTD |
PMID:34122009 |
|
NCBI chr11:30,864,896...30,891,125
Ensembl chr11:30,865,889...30,891,125
|
|
G |
Gatad2b |
GATA zinc finger domain containing 2B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GATAD2B protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,748,594...175,829,837
Ensembl chr 2:175,749,433...175,825,542
|
|
G |
Gda |
guanine deaminase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of GDA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of GFPT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G |
Ggct |
gamma-glutamyl cyclotransferase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GGCT protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277
|
|
G |
Glrx3 |
glutaredoxin 3 |
increases expression |
ISO |
Benztropine results in increased expression of GLRX3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:192,241,707...192,272,012
Ensembl chr 1:192,241,701...192,272,010
|
|
G |
Gls |
glutaminase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GLS protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gna12 |
G protein subunit alpha 12 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GNA12 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:13,805,580...13,886,255
Ensembl chr12:13,805,698...13,886,255
|
|
G |
Golga4 |
golgin A4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of GOLGA4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:118,208,200...118,285,003
|
|
G |
Golgb1 |
golgin B1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GOLGB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:63,843,179...63,900,665
Ensembl chr11:63,843,986...63,900,770
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of GOT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
increases expression |
ISO |
Benztropine results in increased expression of GPI protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Gpkow |
G patch domain and KOW motifs |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GPKOW protein |
CTD |
PMID:34122009 |
|
NCBI chr X:14,791,601...14,806,384
Ensembl chr X:14,791,610...14,806,384
|
|
G |
Gtf2e1 |
general transcription factor IIE subunit 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of GTF2E1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:63,182,073...63,215,349
Ensembl chr11:63,182,349...63,213,942
|
|
G |
Gtf2f1 |
general transcription factor IIF subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GTF2F1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:1,844,027...1,853,455
Ensembl chr 9:1,843,901...1,853,423
|
|
G |
Gtpbp4 |
GTP binding protein 4 |
increases expression |
ISO |
Benztropine results in increased expression of GTPBP4 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:61,308,033...61,328,184
Ensembl chr17:61,308,014...61,418,009
|
|
G |
Gys1 |
glycogen synthase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of GYS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:95,915,443...95,935,292
Ensembl chr 1:95,915,443...95,935,292
|
|
G |
H2ac20 |
H2A clustered histone 20 |
increases expression |
ISO |
Benztropine results in increased expression of H2AC20 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:183,779,879...183,780,357
|
|
G |
H2aj |
H2A.J histone |
increases expression |
ISO |
Benztropine results in increased expression of H2AJ protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:169,675,718...169,676,202
Ensembl chr 4:169,675,752...169,677,006
|
|
G |
Hacd3 |
3-hydroxyacyl-CoA dehydratase 3 |
increases expression |
ISO |
Benztropine results in increased expression of HACD3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:65,501,240...65,538,507
Ensembl chr 8:65,501,240...65,538,507
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
increases expression |
ISO |
Benztropine results in increased expression of HADHB protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Hars1 |
histidyl-tRNA synthetase 1 |
increases expression |
ISO |
Benztropine results in increased expression of HARS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:28,381,649...28,398,699
Ensembl chr18:28,381,655...28,398,740
|
|
G |
Hat1 |
histone acetyltransferase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of HAT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
|
|
G |
Hcfc1 |
host cell factor C1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of HCFC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:151,687,779...151,712,688
Ensembl chr X:151,687,779...151,712,638
|
|
G |
Hmcn2 |
hemicentin 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of HMCN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:14,588,353...14,738,320
Ensembl chr 3:14,588,662...14,738,025
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
decreases expression |
ISO |
Benztropine results in decreased expression of HNRNPD protein |
CTD |
PMID:34122009 |
|
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of HNRNPK protein |
CTD |
PMID:34122009 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of HPS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
|
|
G |
Hsd17b12 |
hydroxysteroid (17-beta) dehydrogenase 12 |
increases expression |
ISO |
Benztropine results in increased expression of HSD17B12 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of HSD17B4 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of HSP90B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of IDI1 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Benztropine results in decreased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Benztropine results in decreased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Benztropine results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Jam3 |
junctional adhesion molecule 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of JAM3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:25,508,461...25,569,306
Ensembl chr 8:25,507,057...25,569,355
|
|
G |
Jpt2 |
Jupiter microtubule associated homolog 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of JPT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:13,963,135...13,983,212
Ensembl chr10:13,963,137...13,983,170
|
|
G |
Kars1 |
lysyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of KARS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:39,957,846...39,976,837
Ensembl chr19:39,957,846...39,977,632
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Benztropine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO |
Benztropine results in decreased expression of KCTD12 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Khdrbs1 |
KH RNA binding domain containing, signal transduction associated 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of KHDRBS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:142,051,844...142,089,175
Ensembl chr 5:142,063,570...142,089,180
|
|
G |
Kif5c |
kinesin family member 5C |
decreases expression |
ISO |
Benztropine results in decreased expression of KIF5C protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413
|
|
G |
Klhdc2 |
kelch domain containing 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of KLHDC2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:87,777,183...87,791,609
Ensembl chr 6:87,777,183...87,804,187
|
|
G |
Klhl41 |
kelch-like family member 41 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of KLHL41 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:54,434,291...54,447,415
Ensembl chr 3:54,434,234...54,449,222
|
|
G |
Kpna4 |
karyopherin subunit alpha 4 |
increases expression |
ISO |
Benztropine results in increased expression of KPNA4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081
|
|
G |
Ktn1 |
kinectin 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of KTN1 protein Benztropine results in decreased expression of KTN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:20,913,665...21,002,588
Ensembl chr15:20,914,642...21,002,578
|
|
G |
Lactb2 |
lactamase, beta 2 |
increases expression |
ISO |
Benztropine results in increased expression of LACTB2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:5,569,080...5,591,843
Ensembl chr 5:5,569,067...5,596,429
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of LAMB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamc1 |
laminin subunit gamma 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of LAMC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:65,374,372...65,501,492
Ensembl chr13:65,374,372...65,501,492
|
|
G |
Lima1 |
LIM domain and actin binding 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of LIMA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:130,901,717...131,001,512
Ensembl chr 7:130,901,717...131,001,473
|
|
G |
Lipa |
lipase A, lysosomal acid type |
increases expression |
ISO |
Benztropine results in increased expression of LIPA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633
|
|
G |
Lmod2 |
leiomodin 2 |
increases expression |
ISO |
Benztropine results in increased expression of LMOD2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:53,067,428...53,075,124
Ensembl chr 4:53,067,428...53,075,120
|
|
G |
Lss |
lanosterol synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of LSS protein |
CTD |
PMID:34122009 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Lta4h |
leukotriene A4 hydrolase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of LTA4H protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:27,969,796...28,001,600
Ensembl chr 7:27,969,789...28,001,600
|
|
G |
Luc7l |
LUC7-like |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of LUC7L protein |
CTD |
PMID:34122009 |
|
NCBI chr10:15,273,340...15,307,131
Ensembl chr10:15,273,348...15,303,112
|
|
G |
Magea9 |
MAGE family member A9 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of MAGEA9 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:142,619,282...142,624,654
Ensembl chr X:142,619,395...142,624,653
|
|
G |
Maged2 |
MAGE family member D2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of MAGED2 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:19,733,593...19,741,769
Ensembl chr X:19,733,597...19,740,477
|
|
G |
Map1s |
microtubule-associated protein 1S |
increases expression |
ISO |
Benztropine results in increased expression of MAP1S protein |
CTD |
PMID:34122009 |
|
NCBI chr16:18,516,759...18,527,777
Ensembl chr16:18,517,574...18,527,988
|
|
G |
Map4 |
microtubule-associated protein 4 |
decreases expression |
ISO |
Benztropine results in decreased expression of MAP4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:109,925,233...110,064,370
Ensembl chr 8:109,925,575...110,064,362
|
|
G |
Mapre1 |
microtubule-associated protein, RP/EB family, member 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of MAPRE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:142,218,846...142,246,990
Ensembl chr 3:142,212,955...142,246,983
|
|
G |
Marcksl1 |
MARCKS-like 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of MARCKSL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:141,851,491...141,853,814
Ensembl chr 5:141,850,110...141,853,817
|
|
G |
Mat2b |
methionine adenosyltransferase 2 non-catalytic beta subunit |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of MAT2B protein |
CTD |
PMID:34122009 |
|
NCBI chr10:25,106,928...25,122,982
Ensembl chr10:25,106,930...25,122,777
|
|
G |
Mboat7 |
membrane bound O-acyltransferase domain containing 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of MBOAT7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:65,525,206...65,539,538
Ensembl chr 1:65,525,213...65,539,538
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of MDH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
Benztropine results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Metap2 |
methionyl aminopeptidase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of METAP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:28,412,429...28,440,458
Ensembl chr 7:28,411,608...28,440,434
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases expression |
ISO |
Benztropine results in increased expression of MIF protein |
CTD |
PMID:34122009 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mtdh |
metadherin |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of MTDH protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:65,306,464...65,365,647
Ensembl chr 7:65,306,400...65,364,413
|
|
G |
Mthfd1l |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of MTHFD1L protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:40,443,926...40,632,911
Ensembl chr 1:40,444,008...40,632,905
|
|
G |
Myh3 |
myosin heavy chain 3 |
increases expression |
ISO |
Benztropine results in increased expression of MYH3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:51,770,177...51,793,994
Ensembl chr10:51,770,177...51,793,992
|
|
G |
Nat10 |
N-acetyltransferase 10 |
decreases expression |
ISO |
Benztropine results in decreased expression of NAT10 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:90,111,643...90,149,891
Ensembl chr 3:90,111,645...90,149,927
|
|
G |
Ncbp1 |
nuclear cap binding protein subunit 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of NCBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:60,416,023...60,449,004
Ensembl chr 5:60,415,982...60,449,089
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of NECTIN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:79,372,123...79,407,379
Ensembl chr 1:79,372,119...79,407,360
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
increases expression |
ISO |
Benztropine results in increased expression of NNMT protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
|
|
G |
Noc2l |
NOC2-like nucleolar associated transcriptional repressor |
increases expression |
ISO |
Benztropine results in increased expression of NOC2L protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:166,820,150...166,831,949
Ensembl chr 5:166,820,161...166,831,949
|
|
G |
Nsf |
N-ethylmaleimide sensitive factor, vesicle fusing ATPase |
decreases expression |
ISO |
Benztropine results in decreased expression of NSF protein |
CTD |
PMID:34122009 |
|
NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386
|
|
G |
Nsfl1c |
NSFL1 cofactor |
decreases expression |
ISO |
Benztropine results in decreased expression of NSFL1C protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870
|
|
G |
Numa1 |
nuclear mitotic apparatus protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of NUMA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:156,297,907...156,372,855
Ensembl chr 1:156,326,259...156,372,855
|
|
G |
Nup153 |
nucleoporin 153 |
increases expression |
ISO |
Benztropine results in increased expression of NUP153 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:17,972,217...18,024,876
Ensembl chr17:17,972,217...18,024,876
|
|
G |
Nup50 |
nucleoporin 50 |
increases expression |
ISO |
Benztropine results in increased expression of NUP50 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:116,047,960...116,065,231
Ensembl chr 7:116,048,021...116,066,905
|
|
G |
Nup54 |
nucleoporin 54 |
decreases expression |
ISO |
Benztropine results in decreased expression of NUP54 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:15,617,630...15,636,029
Ensembl chr14:15,617,679...15,636,028
|
|
G |
Nup93 |
nucleoporin 93 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of NUP93 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:10,684,214...10,788,009
Ensembl chr19:10,682,075...10,788,026
|
|
G |
Nxf1 |
nuclear RNA export factor 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of NXF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,655,442...205,668,637
Ensembl chr 1:205,655,375...205,668,636
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of OAT protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Ogdh |
oxoglutarate dehydrogenase |
decreases expression |
ISO |
Benztropine results in decreased expression of OGDH protein |
CTD |
PMID:34122009 |
|
NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
|
|
G |
Ola1 |
Obg-like ATPase 1 |
increases expression |
ISO |
Benztropine results in increased expression of OLA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:57,966,896...58,085,955
Ensembl chr 3:57,966,896...58,084,480
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
decreases expression |
ISO |
Benztropine results in decreased expression of P4HB protein |
CTD |
PMID:34122009 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PA2G4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PAFAH1B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
|
|
G |
Pag1 |
phosphoprotein membrane anchor with glycosphingolipid microdomains 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PAG1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:91,935,378...92,076,937
Ensembl chr 2:92,057,216...92,069,849
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of PARP1 protein Benztropine results in decreased expression of PARP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pc |
pyruvate carboxylase |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of PC protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pcbp1 |
poly(rC) binding protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PCBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:118,972,698...118,974,705
Ensembl chr 4:118,972,661...118,976,500
|
|
G |
Pcbp2 |
poly(rC) binding protein 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of PCBP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:133,605,375...133,631,312
Ensembl chr 7:133,605,573...133,629,863
|
|
G |
Pcdhga2 |
protocadherin gamma subfamily A, 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of PCDHGA2 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:29,493,954...29,667,865
Ensembl chr18:29,493,954...29,667,868
|
|
G |
Pcmt1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PCMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:2,111,756...2,160,354
Ensembl chr 1:2,111,763...2,159,201
|
|
G |
Pcnp |
PEST proteolytic signal containing nuclear protein |
increases expression |
ISO |
Benztropine results in increased expression of PCNP protein |
CTD |
PMID:34122009 |
|
NCBI chr11:44,592,766...44,607,372
Ensembl chr11:44,592,742...44,607,348
|
|
G |
Pdcl3 |
phosducin-like 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of PDCL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:41,234,322...41,243,769
Ensembl chr 9:41,234,234...41,243,735
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of PDIA3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdia6 |
protein disulfide isomerase family A, member 6 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PDIA6 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613
|
|
G |
Pdlim5 |
PDZ and LIM domain 5 |
decreases expression |
ISO |
Benztropine results in decreased expression of PDLIM5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:230,952,251...231,120,329
Ensembl chr 2:230,952,248...231,120,275
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PEBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Pfn1 |
profilin 1 |
increases expression |
ISO |
Benztropine results in increased expression of PFN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PGK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Pgm3 |
phosphoglucomutase 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PGM3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:87,518,317...87,536,021
Ensembl chr 8:87,517,701...87,536,022
|
|
G |
Phf14 |
PHD finger protein 14 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PHF14 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:40,009,691...40,195,877
Ensembl chr 4:40,009,264...40,195,885
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
decreases expression |
ISO |
Benztropine results in decreased expression of PHGDH protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Benztropine results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Pin1 |
peptidylprolyl cis/trans isomerase, NIMA-interacting 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PIN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:19,189,408...19,200,785
Ensembl chr 8:19,189,373...19,200,785
|
|
G |
Pmpca |
peptidase, mitochondrial processing subunit alpha |
increases expression |
ISO |
Benztropine results in increased expression of PMPCA protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:9,207,731...9,216,846
Ensembl chr 3:9,207,717...9,216,844
|
|
G |
Pnma1 |
PNMA family member 1 |
increases expression |
ISO |
Benztropine results in increased expression of PNMA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:103,782,244...103,784,029
Ensembl chr 6:103,773,889...103,784,567
|
|
G |
Pnma8a |
PNMA family member 8A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PNMA8A protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:77,629,272...77,643,156
Ensembl chr 1:77,639,423...77,642,082
|
|
G |
Pon3 |
paraoxonase 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PON3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855
|
|
G |
Ppa1 |
inorganic pyrophosphatase 1 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PPA1 protein Benztropine results in increased expression of PPA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:29,590,733...29,617,711
Ensembl chr20:29,590,707...29,619,215
|
|
G |
Ppm1f |
protein phosphatase, Mg2+/Mn2+ dependent, 1F |
decreases expression |
ISO |
Benztropine results in decreased expression of PPM1F protein |
CTD |
PMID:34122009 |
|
NCBI chr11:84,064,422...84,094,410
Ensembl chr11:84,064,420...84,094,340
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of PPP1R12A protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ppp1r14b |
protein phosphatase 1, regulatory (inhibitor) subunit 14B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PPP1R14B protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:204,165,210...204,167,320
Ensembl chr 1:204,163,299...204,167,319
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
increases expression |
ISO |
Benztropine results in increased expression of PPP3CA protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PRKAR2A protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:109,393,189...109,458,832
Ensembl chr 8:109,395,833...109,455,628
|
|
G |
Prkcsh |
PRKCSH beta subunit of glucosidase II |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of PRKCSH protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PRMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345
|
|
G |
Prpf6 |
pre-mRNA processing factor 6 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of PRPF6 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:168,706,952...168,771,191
Ensembl chr 3:168,704,299...168,774,991
|
|
G |
Psma1 |
proteasome 20S subunit alpha 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PSMA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:168,442,421...168,453,440
Ensembl chr 1:168,440,936...168,453,472
|
|
G |
Psmb7 |
proteasome 20S subunit beta 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of PSMB7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:22,357,777...22,417,748
Ensembl chr 3:22,354,698...22,417,937
|
|
G |
Psmc1 |
proteasome 26S subunit, ATPase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of PSMC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:119,392,833...119,405,233
Ensembl chr 6:119,392,855...119,410,123
|
|
G |
Psmc3 |
proteasome 26S subunit, ATPase 3 |
increases expression |
ISO |
Benztropine results in increased expression of PSMC3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:77,031,825...77,037,207
Ensembl chr 3:77,031,825...77,043,358
|
|
G |
Psmd7 |
proteasome 26S subunit, non-ATPase 7 |
increases expression |
ISO |
Benztropine results in increased expression of PSMD7 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:35,494,317...35,501,605
Ensembl chr19:35,494,316...35,501,588
|
|
G |
Ptcd3 |
Pentatricopeptide repeat domain 3 |
increases expression multiple interactions |
ISO |
Benztropine results in increased expression of PTCD3 protein [Cuprizone co-treated with Benztropine] results in decreased expression of PTCD3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:103,922,440...103,957,445
Ensembl chr 4:103,920,566...103,957,538
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk7 |
protein tyrosine kinase 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of PTK7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:14,352,155...14,418,473
Ensembl chr 9:14,351,202...14,418,494
|
|
G |
Puf60 |
poly-U binding splicing factor 60 |
decreases expression |
ISO |
Benztropine results in decreased expression of PUF60 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:107,782,799...107,793,759
Ensembl chr 7:107,782,770...107,794,531
|
|
G |
Pwp2 |
PWP2, small subunit processome component |
increases expression |
ISO |
Benztropine results in increased expression of PWP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:10,499,332...10,512,965
Ensembl chr20:10,499,363...10,513,640
|
|
G |
Pycr1 |
pyrroline-5-carboxylate reductase 1 |
increases expression |
ISO |
Benztropine results in increased expression of PYCR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:105,917,732...105,922,658
Ensembl chr10:105,917,680...105,922,549
|
|
G |
Qdpr |
quinoid dihydropteridine reductase |
decreases expression |
ISO |
Benztropine results in decreased expression of QDPR protein |
CTD |
PMID:34122009 |
|
NCBI chr14:65,670,251...65,683,853
Ensembl chr14:65,670,131...65,683,854
|
|
G |
Rack1 |
receptor for activated C kinase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of RACK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975
|
|
G |
Rbm15 |
RNA binding motif protein 15 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of RBM15 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:194,945,974...194,954,498
Ensembl chr 2:194,945,974...194,954,703
|
|
G |
Ric8a |
RIC8 guanine nucleotide exchange factor A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of RIC8A protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:195,935,162...195,941,469
Ensembl chr 1:195,935,349...195,941,467
|
|
G |
Rpl10a |
ribosomal protein L10A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPL10A protein |
CTD |
PMID:34122009 |
|
NCBI chr20:6,388,800...6,391,358
Ensembl chr20:6,385,823...6,391,357
|
|
G |
Rpl19 |
ribosomal protein L19 |
increases expression |
ISO |
Benztropine results in increased expression of RPL19 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:83,022,503...83,026,030
Ensembl chr10:83,019,257...83,052,112
|
|
G |
Rpl24 |
ribosomal protein L24 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPL24 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:44,653,937...44,659,346
Ensembl chr11:44,653,937...44,659,370
|
|
G |
Rpl30 |
ribosomal protein L30 |
increases expression |
ISO |
Benztropine results in increased expression of RPL30 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:65,648,266...65,651,401
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363
|
|
G |
Rpl7a |
ribosomal protein L7A |
decreases expression |
ISO |
Benztropine results in decreased expression of RPL7A protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:10,239,026...10,241,703
Ensembl chr 3:10,239,001...10,241,716
|
|
G |
Rplp1 |
ribosomal protein lateral stalk subunit P1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPLP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:62,394,008...62,395,341
Ensembl chr 8:62,393,177...62,395,339
|
|
G |
Rps12 |
ribosomal protein S12 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPS12 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
|
|
G |
Rps18 |
ribosomal protein S18 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of RPS18 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:4,931,427...4,935,538
Ensembl chr10:101,204,500...101,205,146 Ensembl chr20:101,204,500...101,205,146
|
|
G |
Rps27 |
ribosomal protein S27 |
increases expression |
ISO |
Benztropine results in increased expression of RPS27 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964
|
|
G |
Rps27a |
ribosomal protein S27a |
increases expression |
ISO |
Benztropine results in increased expression of RPS27A protein |
CTD |
PMID:34122009 |
|
NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011 Ensembl chr 5:103,285,734...103,288,011
|
|
G |
Rps3 |
ribosomal protein S3 |
decreases expression |
ISO |
Benztropine results in decreased expression of RPS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:153,778,363...153,783,663
Ensembl chr 1:153,777,472...153,783,680
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
increases expression |
ISO |
Benztropine results in increased expression of RUVBL2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SAE1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986
|
|
G |
Sars1 |
seryl-tRNA synthetase 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SARS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:196,065,543...196,081,240
Ensembl chr 2:196,065,430...196,081,277
|
|
G |
Satb2 |
SATB homeobox 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of SATB2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:58,348,027...58,534,256
Ensembl chr 9:58,350,246...58,530,707
|
|
G |
Sccpdh |
saccharopine dehydrogenase (putative) |
decreases expression |
ISO |
Benztropine results in decreased expression of SCCPDH protein |
CTD |
PMID:34122009 |
|
NCBI chr13:91,400,120...91,421,875
Ensembl chr13:91,400,190...91,422,222
|
|
G |
Sdcbp |
syndecan binding protein |
decreases expression |
ISO |
Benztropine results in decreased expression of SDCBP protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572
|
|
G |
Sec23a |
Sec23 homolog A, COPII coat complex component |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of SEC23A protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:76,658,793...76,706,125
Ensembl chr 6:76,658,427...76,706,035
|
|
G |
Sec61b |
SEC61 translocon subunit beta |
increases expression |
ISO |
Benztropine results in increased expression of SEC61B protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:61,773,594...61,781,804
Ensembl chr 5:61,773,594...61,781,804
|
|
G |
Sec63 |
SEC63 homolog, protein translocation regulator |
increases expression |
ISO |
Benztropine results in increased expression of SEC63 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:46,245,101...46,314,055
Ensembl chr20:46,245,101...46,314,055
|
|
G |
Serbp1 |
Serpine1 mRNA binding protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SERBP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:96,401,587...96,421,816
Ensembl chr 4:96,401,477...96,421,813
|
|
G |
Serpinb3a |
serpin family B member 3A |
increases expression |
ISO |
Benztropine results in increased expression of SERPINB4 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:23,241,303...23,246,328
Ensembl chr13:23,236,972...23,246,985
|
|
G |
Sf1 |
splicing factor 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330
|
|
G |
Sf3b3 |
splicing factor 3b, subunit 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of SF3B3 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:38,782,749...38,820,271
Ensembl chr19:38,783,040...38,820,245
|
|
G |
Sgca |
sarcoglycan, alpha |
decreases expression |
ISO |
Benztropine results in decreased expression of SGCA protein |
CTD |
PMID:34122009 |
|
NCBI chr10:79,904,698...79,922,808
Ensembl chr10:79,908,738...79,922,813
|
|
G |
Sh3pxd2b |
SH3 and PX domains 2B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SH3PXD2B protein |
CTD |
PMID:34122009 |
|
NCBI chr10:16,918,611...17,027,499
Ensembl chr10:16,918,679...17,005,170
|
|
G |
Shmt1 |
serine hydroxymethyltransferase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SHMT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:45,468,698...45,490,833
Ensembl chr10:45,468,700...45,497,820
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Benztropine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc25a5-ps11 |
solute carrier family 25 member 5, pseudogene 11 |
increases expression |
ISO |
Benztropine results in increased expression of SLC25A6 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:68,571,222...68,572,461
Ensembl chr18:68,571,300...68,572,199
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SLC2A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of SLC38A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of SLC3A2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
Benztropine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] |
CTD |
PMID:17250655 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Benztropine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Smarcb1 |
SWI/SNF related BAF chromatin remodeling complex subunit B1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SMARCB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:12,741,164...12,763,616
Ensembl chr20:12,741,477...12,763,620
|
|
G |
Smc3 |
structural maintenance of chromosomes 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SMC3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:252,601,422...252,644,522
Ensembl chr 1:252,601,753...252,644,522
|
|
G |
Smu1 |
SMU1, DNA replication regulator and spliceosomal factor |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SMU1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:55,856,691...55,875,262
Ensembl chr 5:55,856,246...55,875,300
|
|
G |
Snrnp200 |
small nuclear ribonucleoprotein U5 subunit 200 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SNRNP200 protein Benztropine results in increased expression of SNRNP200 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:114,428,854...114,458,194
Ensembl chr 3:114,428,854...114,458,182
|
|
G |
Snrpa |
small nuclear ribonucleoprotein polypeptide A |
increases expression |
ISO |
Benztropine results in increased expression of SNRPA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:82,481,770...82,490,540
Ensembl chr 1:82,481,770...82,490,538
|
|
G |
Snrpd2 |
small nuclear ribonucleoprotein D2 polypeptide |
increases expression |
ISO |
Benztropine results in increased expression of SNRPD2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:78,798,377...78,801,227
Ensembl chr 1:78,798,377...78,803,351
|
|
G |
Srek1 |
splicing regulatory glutamic acid and lysine rich protein 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of SREK1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:34,849,548...34,885,120
Ensembl chr 2:34,852,458...34,884,972
|
|
G |
Srsf5 |
serine and arginine rich splicing factor 5 |
increases expression |
ISO |
Benztropine results in increased expression of SRSF5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of STAT3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stim1 |
stromal interaction molecule 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of STIM1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Benztropine results in decreased expression of STIP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Strap |
serine/threonine kinase receptor associated protein |
decreases expression |
ISO |
Benztropine results in decreased expression of STRAP protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:170,646,042...170,660,291
Ensembl chr 4:170,646,001...170,660,828
|
|
G |
Stub1 |
STIP1 homology and U-box containing protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of STUB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:14,850,765...14,853,046
Ensembl chr10:14,850,765...14,853,046
|
|
G |
Suclg1 |
succinate-CoA ligase GDP/ADP-forming subunit alpha |
decreases expression |
ISO |
Benztropine results in decreased expression of SUCLG1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:105,308,236...105,337,595
Ensembl chr 4:105,308,039...105,337,600
|
|
G |
Sumo2 |
small ubiquitin-like modifier 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of SUMO2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:100,771,941...100,784,503
Ensembl chr10:100,686,797...100,784,513
|
|
G |
Sun1 |
Sad1 and UNC84 domain containing 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of SUN1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:15,396,378...15,441,277
Ensembl chr12:15,396,381...15,441,571
|
|
G |
Syncrip |
synaptotagmin binding, cytoplasmic RNA interacting protein |
decreases expression |
ISO |
Benztropine results in decreased expression of SYNCRIP protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:89,402,487...89,435,517
Ensembl chr 8:89,402,866...89,435,515
|
|
G |
Tagln2 |
transgelin 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of TAGLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:84,966,980...84,973,973
Ensembl chr13:84,967,009...84,973,972
|
|
G |
Tbcb |
tubulin folding cofactor B |
decreases expression |
ISO |
Benztropine results in decreased expression of TBCB protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:85,477,639...85,483,488
Ensembl chr 1:85,477,640...85,483,488
|
|
G |
Tcaf1 |
TRPM8 channel-associated factor 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TCAF1 protein Benztropine results in decreased expression of TCAF1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:71,589,674...71,639,274
Ensembl chr 4:71,591,200...71,613,309
|
|
G |
Tgoln2 |
trans-golgi network protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TGOLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164
|
|
G |
Tln2 |
talin 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of TLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:67,830,920...68,252,240
Ensembl chr 8:67,834,326...68,252,219
|
|
G |
Tmpo |
thymopoietin |
decreases expression |
ISO |
Benztropine results in decreased expression of TMPO protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Tnks1bp1 |
tankyrase 1 binding protein 1 |
multiple interactions decreases expression |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TNKS1BP1 protein Benztropine results in decreased expression of TNKS1BP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:70,135,335...70,160,071
Ensembl chr 3:70,137,837...70,160,038
|
|
G |
Tomm34 |
translocase of outer mitochondrial membrane 34 |
decreases expression multiple interactions |
ISO |
Benztropine results in decreased expression of TOMM34 protein [Cuprizone co-treated with Benztropine] results in increased expression of TOMM34 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:152,729,345...152,746,295
Ensembl chr 3:152,729,349...152,746,373
|
|
G |
Top1mt |
DNA topoisomerase I mitochondrial |
increases expression |
ISO |
Benztropine results in increased expression of TOP1MT protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:107,338,092...107,368,125
Ensembl chr 7:107,342,527...107,366,049
|
|
G |
Tpm2 |
tropomyosin 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of TPM2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:57,770,919...57,780,278
Ensembl chr 5:57,770,864...57,779,992
|
|
G |
Tpm3 |
tropomyosin 3 |
decreases expression |
ISO |
Benztropine results in decreased expression of TPM3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,517,198...175,545,014
Ensembl chr 2:175,517,226...175,545,013
|
|
G |
Tpr |
translocated promoter region, nuclear basket protein |
decreases expression |
ISO |
Benztropine results in decreased expression of TPR protein |
CTD |
PMID:34122009 |
|
NCBI chr13:62,424,312...62,487,502
Ensembl chr13:62,424,312...62,487,496
|
|
G |
Trim28 |
tripartite motif-containing 28 |
decreases expression multiple interactions |
ISO |
Benztropine results in decreased expression of TRIM28 protein [Cuprizone co-treated with Benztropine] results in increased expression of TRIM28 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:73,652,441...73,659,388
Ensembl chr 1:73,652,709...73,659,380
|
|
G |
Tspan3 |
tetraspanin 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of TSPAN3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:56,546,067...56,569,815
Ensembl chr 8:56,546,069...56,569,880
|
|
G |
Ttc21a |
tetratricopeptide repeat domain 21A |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of TTC21A protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:119,667,044...119,702,028
Ensembl chr 8:119,666,933...119,702,456
|
|
G |
Ttyh2 |
tweety family member 2 |
increases expression |
ISO |
Benztropine results in increased expression of TTYH2 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:99,709,063...99,753,449
Ensembl chr10:99,709,007...99,753,444
|
|
G |
Ttyh3 |
tweety family member 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TTYH3 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:13,996,831...14,025,457
Ensembl chr12:13,997,045...14,025,459
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
increases expression |
ISO |
Benztropine results in increased expression of TUBB protein |
CTD |
PMID:34122009 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Twf2 |
twinfilin actin-binding protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of TWF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:106,845,253...106,858,298
Ensembl chr 8:106,845,253...106,858,298
|
|
G |
Txlna |
taxilin alpha |
decreases expression |
ISO |
Benztropine results in decreased expression of TXLNA protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:141,969,337...141,985,054
Ensembl chr 5:141,969,346...141,984,583
|
|
G |
Tyms |
thymidylate synthetase |
increases expression |
ISO |
Benztropine results in increased expression of TYMS protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
U2af2 |
U2 small nuclear RNA auxiliary factor 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of U2AF2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492
|
|
G |
Uba2 |
ubiquitin-like modifier activating enzyme 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of UBA2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:86,775,239...86,802,685
Ensembl chr 1:86,775,244...86,802,682
|
|
G |
Ubap2l |
ubiquitin associated protein 2-like |
decreases expression |
ISO |
Benztropine results in decreased expression of UBAP2L protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:175,438,703...175,494,085
Ensembl chr 2:175,438,703...175,493,998
|
|
G |
Ubc |
ubiquitin C |
increases expression |
ISO |
Benztropine results in increased expression of UBC protein |
CTD |
PMID:34122009 |
|
NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
G |
Ubqln2 |
ubiquilin 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of UBQLN2 protein |
CTD |
PMID:34122009 |
|
NCBI chr X:17,853,086...17,856,505
Ensembl chr X:17,853,114...17,856,505
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of UCHL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590
|
|
G |
Uchl3 |
ubiquitin C-terminal hydrolase L3 |
decreases expression |
ISO |
Benztropine results in decreased expression of UCHL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:78,485,304...78,527,355
Ensembl chr15:78,485,315...78,527,355 Ensembl chr 3:78,485,315...78,527,355
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
decreases expression |
ISO |
Benztropine results in decreased expression of UGDH protein |
CTD |
PMID:34122009 |
|
NCBI chr14:42,848,704...42,872,351
Ensembl chr14:42,848,854...42,872,354
|
|
G |
Unc45b |
unc-45 myosin chaperone B |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of UNC45B protein |
CTD |
PMID:34122009 |
|
NCBI chr10:67,845,464...67,873,143
Ensembl chr10:67,845,462...67,873,389
|
|
G |
Uqcrc2 |
ubiquinol cytochrome c reductase core protein 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of UQCRC2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453
|
|
G |
Uso1 |
USO1 vesicle transport factor |
decreases expression |
ISO |
Benztropine results in decreased expression of USO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:15,866,638...15,932,185
Ensembl chr14:15,866,638...15,932,171
|
|
G |
Usp10 |
ubiquitin specific peptidase 10 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of USP10 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:47,972,858...48,014,900
Ensembl chr19:47,972,611...48,014,897
|
|
G |
Usp14 |
ubiquitin specific peptidase 14 |
increases expression |
ISO |
Benztropine results in increased expression of USP14 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519
|
|
G |
Utp18 |
UTP18 small subunit processome component |
increases expression |
ISO |
Benztropine results in increased expression of UTP18 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:78,811,879...78,839,338
Ensembl chr10:78,811,880...78,839,627
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
decreases expression |
ISO |
Benztropine results in decreased expression of VASP protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of WARS1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Wdr12 |
WD repeat domain 12 |
decreases expression |
ISO |
Benztropine results in decreased expression of WDR12 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:61,475,498...61,502,762
Ensembl chr 9:61,475,517...61,502,469
|
|
G |
Xirp2 |
xin actin-binding repeat containing 2 |
decreases expression |
ISO |
Benztropine results in decreased expression of XIRP2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:52,126,213...52,213,094
Ensembl chr 3:51,870,092...52,213,091
|
|
G |
Xpo7 |
exportin 7 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in increased expression of XPO7 protein |
CTD |
PMID:34122009 |
|
NCBI chr15:45,742,053...45,828,050
Ensembl chr15:45,742,053...45,828,050
|
|
G |
Ywhaq |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta |
increases expression |
ISO |
Benztropine results in increased expression of YWHAQ protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:40,935,714...40,966,240
Ensembl chr 6:40,935,949...40,966,273
|
|
G |
Zbtb42 |
zinc finger and BTB domain containing 42 |
multiple interactions |
ISO |
[Cuprizone co-treated with Benztropine] results in decreased expression of ZBTB42 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:131,734,257...131,742,459
Ensembl chr 6:131,738,356...131,742,685
|
|
G |
Zfr |
zinc finger RNA binding protein |
decreases expression |
ISO |
Benztropine results in decreased expression of ZFR protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:61,137,611...61,200,322
|
|
G |
Zkscan7 |
zinc finger with KRAB and SCAN domains 7 |
decreases expression |
ISO |
Benztropine results in decreased expression of ZKSCAN7 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:122,501,938...122,519,600
Ensembl chr 8:122,502,218...122,519,600
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Biperiden results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
Biperiden results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
EXP |
Biperiden binds to and results in decreased activity of CHRM1 protein |
CTD |
PMID:21336581 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Biperiden results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Biperiden results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Biperiden results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
Biperiden results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
Biperiden results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
Biperiden results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Biperiden results in increased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
EXP |
Bromocriptine results in increased expression of ABCB1 protein Clozapine inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]; Spiperone inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein] |
CTD |
PMID:9111066 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
increases activity increases expression multiple interactions |
EXP |
Bromocriptine results in increased activity of ABCB1B promoter Bromocriptine results in increased expression of ABCB1B mRNA Clozapine inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; eticlopride inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Pertussis Toxin inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Spiperone inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter] |
CTD |
PMID:9111066 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression multiple interactions |
EXP |
Bromocriptine results in increased expression of AKR1C3 mRNA methyl cellosolve inhibits the reaction [Bromocriptine results in increased expression of AKR1C3 mRNA] |
CTD |
PMID:21427058 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Bromocriptine results in increased expression of ATF3 mRNA; Bromocriptine results in increased expression of ATF3 protein |
CTD |
PMID:21867702 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
Bromocriptine results in increased expression of BAX protein [Bromocriptine co-treated with Octreotide] results in increased expression of BAX protein |
CTD |
PMID:15046398 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases secretion |
ISO |
Bromocriptine results in decreased secretion of BDNF protein |
CTD |
PMID:12770616 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[Bromocriptine co-treated with Estradiol] results in decreased expression of CTNNB1 protein |
CTD |
PMID:11786374 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
EXP |
Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of CYP11A1 mRNA] Bromocriptine results in decreased expression of CYP11A1 protein |
CTD |
PMID:12742521 PMID:21427058 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Bromocriptine results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Bromocriptine results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects binding affects metabolic processing multiple interactions |
ISO |
Bromocriptine binds to CYP3A4 protein CYP3A4 protein affects the metabolism of Bromocriptine Bromocriptine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:15286053 PMID:17198380 PMID:19299527 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dbh |
dopamine beta-hydroxylase |
decreases activity |
ISO |
Bromocriptine results in decreased activity of DBH protein |
CTD |
PMID:501350 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Drd2 |
dopamine receptor D2 |
affects expression affects response to substance multiple interactions decreases expression increases expression increases response to substance |
ISO EXP |
Bromocriptine affects the expression of DRD2 mRNA DRD2 protein affects the susceptibility to Bromocriptine Bromocriptine binds to and results in increased activity of DRD2 mRNA; Bromocriptine promotes the reaction [Clozapine results in decreased expression of DRD2 mRNA] Bromocriptine results in decreased expression of DRD2 mRNA [Clozapine co-treated with Bromocriptine] results in decreased expression of DRD2 mRNA Bromocriptine results in increased expression of DRD2 mRNA DRD2 polymorphism results in increased susceptibility to Bromocriptine |
CTD |
PMID:1534540 PMID:8103596 PMID:15781964 PMID:16901644 PMID:20063113 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
multiple interactions decreases expression |
EXP |
[1-Methyl-4-phenylpyridinium co-treated with Bromocriptine] results in decreased expression of DRD3 mRNA Bromocriptine results in decreased expression of DRD3 mRNA |
CTD |
PMID:17000468 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
[Bromocriptine co-treated with Estradiol] results in increased expression of ESR1 protein |
CTD |
PMID:11786374 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression |
ISO |
Bromocriptine results in increased expression of FSHB protein |
CTD |
PMID:86031 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
decreases expression decreases secretion |
ISO |
Bromocriptine results in decreased expression of GDNF mRNA Bromocriptine results in decreased secretion of GDNF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gh1 |
growth hormone 1 |
increases expression decreases expression |
ISO |
Bromocriptine results in increased expression of GH1 protein Bromocriptine results in decreased expression of GH1 protein |
CTD |
PMID:772175 PMID:3226523 PMID:3745407 PMID:7293648 PMID:19420816 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Bromocriptine results in increased expression of HMOX1 mRNA; Bromocriptine results in increased expression of HMOX1 protein |
CTD |
PMID:21867702 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Bromocriptine binds to and results in decreased activity of HTR7 protein |
CTD |
PMID:18996971 PMID:19509219 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Ins2 |
insulin 2 |
decreases expression |
ISO |
Bromocriptine results in decreased expression of INS protein |
CTD |
PMID:16803851 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression |
ISO |
Bromocriptine results in increased expression of LHB protein |
CTD |
PMID:86031 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Bromocriptine promotes the reaction [Estrogens results in increased phosphorylation of and affects the localization of MAPK1 protein] |
CTD |
PMID:19595700 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Bromocriptine promotes the reaction [Estrogens results in increased phosphorylation of and affects the localization of MAPK3 protein] |
CTD |
PMID:19595700 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases localization |
ISO |
Bromocriptine results in increased localization of NFE2L2 protein |
CTD |
PMID:21867702 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
increases secretion |
ISO |
Bromocriptine results in increased secretion of NGF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of NOS2 protein] |
CTD |
PMID:21867702 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions |
EXP |
Bromocriptine affects the reaction [methyl cellosolve results in increased expression of NR5A2 mRNA] |
CTD |
PMID:21427058 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein] |
CTD |
PMID:15677882 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pomc |
proopiomelanocortin |
decreases expression increases expression multiple interactions |
EXP ISO |
Bromocriptine results in decreased expression of POMC protein alternative form Bromocriptine results in increased expression of POMC mRNA; Bromocriptine results in increased expression of POMC protein modified form Bromocriptine inhibits the reaction [POMC protein results in decreased secretion of Corticosterone] |
CTD |
PMID:1325994 PMID:6274577 PMID:12742521 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions affects localization |
EXP |
Bromocriptine promotes the reaction [Estrogens results in increased expression of and results in increased cleavage of PRKCD protein] Bromocriptine affects the localization of PRKCD protein |
CTD |
PMID:19595700 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prl |
prolactin |
multiple interactions decreases secretion decreases expression |
ISO EXP |
Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Nalorphine results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein] Bromocriptine results in decreased secretion of PRL protein Bromocriptine results in decreased expression of PRL protein Bromocriptine inhibits the reaction [Amisulpride results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Estradiol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [Olanzapine results in increased expression of PRL protein]; Estradiol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Ethanol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein] |
CTD |
PMID:86031 PMID:86795 PMID:90217 PMID:1407345 PMID:1874184 PMID:2042694 PMID:2887062 PMID:3019639 PMID:3208992 PMID:3625096 PMID:3660204 PMID:3745407 PMID:3776530 PMID:4072572 PMID:6441721 PMID:6477585 PMID:6507109 PMID:6669217 PMID:6693536 PMID:6986893 PMID:7106173 PMID:7168914 PMID:7243090 PMID:7670571 PMID:8914150 PMID:11685661 PMID:11786374 PMID:12106810 PMID:12161478 PMID:12742521 PMID:12824819 PMID:15046398 PMID:15677882 PMID:21427058 PMID:38437955 More...
|
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
EXP |
Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of SCARB1 mRNA] |
CTD |
PMID:21427058 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of NOS2 protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein] |
CTD |
PMID:21867702 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Bromocriptine results in decreased expression of STAR protein |
CTD |
PMID:12742521 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
affects localization |
ISO |
Bromocriptine affects the localization of STAT5A protein |
CTD |
PMID:17884938 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
EXP |
Bromocriptine inhibits the reaction [Estradiol results in increased expression of TGFA mRNA] |
CTD |
PMID:1534540 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of TGFB1 protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of TGFB1 protein] |
CTD |
PMID:15677882 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein] Bromocriptine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:11752888 PMID:21867702 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VEGFA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of VEGFA protein] |
CTD |
PMID:15677882 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vip |
vasoactive intestinal peptide |
multiple interactions |
ISO EXP |
Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein] [Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein] |
CTD |
PMID:6441721 PMID:15677882 |
|
NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
ISO |
Cabergoline results in increased expression of BDNF protein |
CTD |
PMID:35104500 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
Cabergoline results in increased expression of CREB1 protein modified form |
CTD |
PMID:35104500 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
Cabergoline binds to and results in increased activity of DRD2 protein |
CTD |
PMID:35104500 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression increases secretion |
ISO |
cabergoline results in increased expression of GDNF mRNA cabergoline results in increased secretion of GDNF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Ngf |
nerve growth factor |
increases expression increases secretion |
ISO |
cabergoline results in increased expression of NGF mRNA cabergoline results in increased secretion of NGF protein |
CTD |
PMID:12770616 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Prl |
prolactin |
decreases expression multiple interactions decreases secretion |
ISO EXP |
cabergoline results in decreased expression of PRL protein Haloperidol inhibits the reaction [cabergoline results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [cabergoline results in decreased secretion of PRL protein] |
CTD |
PMID:2570719 PMID:3745407 PMID:7670571 PMID:15377706 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of BAX protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of BAX protein] Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of BAX protein]] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of BCL2 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein]; Carbidopa inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased cleavage of CASP9 protein]] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation |
ISO EXP |
COMT protein results in increased methylation of Carbidopa |
CTD |
PMID:11160877 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of DDC mRNA] Carbidopa binds to and results in decreased activity of DDC protein |
CTD |
PMID:35151785 PMID:35202708 |
|
NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of DNM1L protein]] |
CTD |
PMID:35202708 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of FIS1 protein]] |
CTD |
PMID:35202708 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein]] |
CTD |
PMID:35202708 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of IL1B protein] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of IL1B protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of IL1B protein] |
CTD |
PMID:34560070 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Maoa |
monoamine oxidase A |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA mRNA]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased expression of MAOA protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in increased expression of MAOA protein]] |
CTD |
PMID:34560070 PMID:35202708 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Mfn1 |
mitofusin 1 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of MFN1 protein]] |
CTD |
PMID:35202708 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mt-atp6 |
mitochondrially encoded ATP synthase membrane subunit 6 |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ATP6 protein]] |
CTD |
PMID:35202708 |
|
NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599
|
|
G |
Mt-cyb |
mitochondrially encoded cytochrome b |
multiple interactions |
ISO |
Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]]; sarpogrelate promotes the reaction [Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYTB protein]] |
CTD |
PMID:35202708 |
|
NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278 NCBI chr MT:14,136...15,278
Ensembl chr MT:14,136...15,278
|
|
G |
Mt-nd1 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]; Carbidopa promotes the reaction [sarpogrelate inhibits the reaction [Carbon Tetrachloride results in decreased expression of ND1 protein]] |
CTD |
PMID:35202708 |
|
NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694 NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of RELA protein] |
CTD |
PMID:34560070 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
EXP |
[Levodopa co-treated with Carbidopa] inhibits the reaction [Reserpine results in increased expression of SNCA protein] |
CTD |
PMID:38229316 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein]; Carbidopa inhibits the reaction [Cisplatin results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:34560070 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased expression of TNF protein] [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Cisplatin results in increased secretion of TNF protein]; Carbidopa inhibits the reaction [Cisplatin results in increased secretion of TNF protein] |
CTD |
PMID:34560070 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tph1 |
tryptophan hydroxylase 1 |
multiple interactions |
ISO |
[sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 mRNA]; [sarpogrelate co-treated with Carbidopa] inhibits the reaction [Carbon Tetrachloride results in increased expression of TPH1 protein] |
CTD |
PMID:35202708 |
|
NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
carbinoxamine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
carbinoxamine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity |
ISO |
Dimenhydrinate results in decreased activity of BCHE protein |
CTD |
PMID:236606 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Dimenhydrinate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Atg5 |
autophagy related 5 |
affects response to substance |
ISO |
ATG5 protein affects the susceptibility to Diphenhydramine |
CTD |
PMID:22310178 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
Protons affects the reaction [Diphenhydramine results in decreased activity of BCHE protein] |
CTD |
PMID:236606 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Ereg |
epiregulin |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [Histamine results in increased expression of F3] |
CTD |
PMID:16009787 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
increases response to substance |
ISO |
GNAI1 results in increased susceptibility to Diphenhydramine |
CTD |
PMID:14614911 |
|
NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
increases response to substance |
ISO |
GNAI2 results in increased susceptibility to Diphenhydramine |
CTD |
PMID:14614911 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions |
ISO EXP |
Diphenhydramine binds to and results in decreased activity of HRH1 protein; Diphenhydramine binds to and results in increased activity of HRH1 protein; Diphenhydramine inhibits the reaction [Pyrilamine binds to HRH1 protein]; HRH1 protein promotes the reaction [Diphenhydramine results in decreased susceptibility to CXCL8 protein] [Diphenhydramine results in decreased activity of HRH1 protein] which results in decreased susceptibility to Erythromycin |
CTD |
PMID:1912125 PMID:2419744 PMID:2461127 PMID:7522859 PMID:9609743 PMID:12856827 More...
|
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Il1b |
interleukin 1 beta |
increases expression decreases expression |
ISO |
Diphenhydramine results in increased expression of IL1B mRNA Diphenhydramine results in decreased expression of IL1B mRNA |
CTD |
PMID:28138970 PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [Histamine results in increased expression of IL6 protein] |
CTD |
PMID:11336536 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases activity |
ISO |
Diphenhydramine results in increased activity of MAPK8 |
CTD |
PMID:17390763 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
[Diphenhydramine co-treated with PK 11195] binds to and results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:20869355 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [Histamine results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:9609743 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16263091 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Diphenhydramine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:16263091 PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Diphenhydramine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16263091 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Diphenhydramine affects the reaction [SLC22A5 gene mutant form affects the transport of and affects the abundance of Pyrilamine]; Diphenhydramine inhibits the reaction [SLC22A5 gene mutant form affects the transport of and affects the abundance of Pyrilamine] |
CTD |
PMID:19821448 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
Diphenhydramine results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
Diphenhydramine results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
|
G |
Acox3 |
acyl-CoA oxidase 3, pristanoyl |
affects binding |
EXP |
entacapone binds to ACOX3 protein |
CTD |
PMID:19783845 |
|
NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
affects binding |
EXP |
entacapone binds to ACSL1 protein |
CTD |
PMID:19783845 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Adprhl1 |
ADP-ribosylhydrolase like 1 |
affects binding |
EXP |
entacapone binds to ADPRHL1 protein |
CTD |
PMID:19783845 |
|
NCBI chr16:76,283,186...76,315,075
Ensembl chr16:76,283,103...76,354,440
|
|
G |
Auh |
AU RNA binding methylglutaconyl-CoA hydratase |
affects binding |
EXP |
entacapone binds to AUH protein |
CTD |
PMID:19783845 |
|
NCBI chr17:12,329,522...12,424,882
Ensembl chr17:12,329,524...12,424,896
|
|
G |
Cltc |
clathrin heavy chain |
affects binding |
EXP |
entacapone binds to CLTC protein |
CTD |
PMID:19783845 |
|
NCBI chr10:71,517,661...71,574,591
Ensembl chr10:71,517,663...71,573,737
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases activity affects binding multiple interactions |
ISO EXP |
entacapone results in decreased activity of COMT protein entacapone binds to COMT protein [entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; entacapone inhibits the reaction [COMT protein results in increased methylation of Levodopa] |
CTD |
PMID:12898346 PMID:15566291 PMID:19783845 PMID:20334432 PMID:23206800 PMID:29688484 More...
|
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
affects binding |
EXP |
entacapone binds to ECHS1 protein |
CTD |
PMID:19783845 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
entacapone results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
decreases expression |
ISO |
entacapone results in decreased expression of GPAM protein |
CTD |
PMID:29688484 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Hbb |
hemoglobin subunit beta |
affects binding |
EXP |
entacapone binds to HBB protein |
CTD |
PMID:19783845 |
|
NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012
|
|
G |
Hsd17b13 |
hydroxysteroid (17-beta) dehydrogenase 13 |
affects binding |
EXP |
entacapone binds to HSD17B13 protein |
CTD |
PMID:19783845 |
|
NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
affects binding |
EXP |
entacapone binds to HSD17B4 protein |
CTD |
PMID:19783845 |
|
NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
entacapone results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
entacapone results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
entacapone results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Pc |
pyruvate carboxylase |
affects binding |
EXP |
entacapone binds to PC protein |
CTD |
PMID:19783845 |
|
NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
decreases expression |
ISO |
entacapone results in decreased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
entacapone results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
decreases expression |
ISO |
entacapone results in decreased expression of SLC7A11 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
decreases expression |
ISO |
entacapone results in decreased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
entacapone inhibits the reaction [SNCA protein binds to SNCA protein] |
CTD |
PMID:20150427 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
affects binding |
EXP |
entacapone binds to SULT2A1 protein |
CTD |
PMID:19783845 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
decreases expression |
ISO |
entacapone results in decreased expression of TNFAIP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of entacapone |
CTD |
PMID:15802387 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of entacapone |
CTD |
PMID:15802387 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation decreases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of entacapone UGT1A9 protein mutant form results in decreased glucuronidation of entacapone |
CTD |
PMID:15044611 PMID:15802387 PMID:16344532 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression decreases activity |
ISO |
Haloperidol inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of ABCB1 mRNA Haloperidol results in decreased activity of ABCB1 protein |
CTD |
PMID:15946544 PMID:16810505 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions decreases expression |
ISO |
Haloperidol inhibits the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin] Haloperidol results in decreased expression of ABCC1 mRNA |
CTD |
PMID:15946544 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Haloperidol inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] |
CTD |
PMID:18834354 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acadvl |
acyl-CoA dehydrogenase, very long chain |
decreases expression |
ISO |
Haloperidol results in decreased expression of ACADVL protein |
CTD |
PMID:34122009 |
|
NCBI chr10:54,732,875...54,738,102
Ensembl chr10:54,732,469...54,738,075
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ACAT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [potassium bromate results in increased activity of ACHE protein] |
CTD |
PMID:37865952 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ACSL3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [potassium bromate results in increased activity of ADA protein] |
CTD |
PMID:37865952 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam1a |
ADAM metallopeptidase domain 1a |
decreases expression |
EXP |
Haloperidol results in decreased expression of ADAM1A mRNA |
CTD |
PMID:16715494 |
|
NCBI chr12:35,017,433...35,020,300
Ensembl chr12:35,017,315...35,020,311
|
|
G |
Adcy5 |
adenylate cyclase 5 |
affects response to substance multiple interactions |
ISO |
ADCY5 protein affects the susceptibility to Haloperidol SCH 23390 inhibits the reaction [ADCY5 protein affects the susceptibility to Haloperidol] |
CTD |
PMID:12223546 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
affects expression |
ISO |
Haloperidol affects the expression of ADCYAP1R1 mRNA |
CTD |
PMID:27900577 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adora2a |
adenosine A2a receptor |
affects response to substance |
ISO |
ADORA2A protein affects the susceptibility to Haloperidol |
CTD |
PMID:11172060 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adsl |
adenylosuccinate lyase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ADSL protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760
|
|
G |
Agpat1 |
1-acylglycerol-3-phosphate O-acyltransferase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of AGPAT1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr20:4,135,955...4,144,880
Ensembl chr20:4,135,957...4,145,278
|
|
G |
Agps |
alkylglycerone phosphate synthase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of AGPS protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:60,747,323...60,845,831
Ensembl chr 3:60,747,323...60,845,830
|
|
G |
Ak4 |
adenylate kinase 4 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of AK4 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:116,039,222...116,099,064
Ensembl chr 5:116,039,616...116,098,618
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AKT1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
increases expression |
EXP |
Haloperidol results in increased expression of AKT2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ALDH18A1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Haloperidol results in increased expression of ALDOA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
increases expression |
EXP |
Haloperidol results in increased expression of ALDOC mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Ankhd1 |
ankyrin repeat and KH domain containing 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of ANKHD1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024
|
|
G |
Ap2a2 |
adaptor related protein complex 2 subunit alpha 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AP2A2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:196,652,315...196,725,609
Ensembl chr 1:196,652,337...196,725,603
|
|
G |
Ap2b1 |
adaptor related protein complex 2 subunit beta 1 |
affects expression |
EXP |
Haloperidol affects the expression of AP2B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:68,099,397...68,205,023
Ensembl chr10:68,099,547...68,205,013
|
|
G |
Ap2m1 |
adaptor related protein complex 2 subunit mu 1 |
increases expression |
ISO |
Haloperidol results in increased expression of AP2M1 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140
|
|
G |
Ap3b1 |
adaptor related protein complex 3 subunit beta 1 |
increases expression |
ISO |
Haloperidol results in increased expression of AP3B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:25,600,069...25,800,937
Ensembl chr 2:25,600,040...25,800,935
|
|
G |
Apod |
apolipoprotein D |
increases expression |
ISO |
Haloperidol results in increased expression of APOD mRNA |
CTD |
PMID:14647396 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of APPL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of ARC mRNA 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of ARC mRNA] |
CTD |
PMID:18208916 PMID:19695244 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Arf1 |
ARF GTPase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARF1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
|
|
G |
Arf3 |
ARF GTPase 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARF3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002
|
|
G |
Arl3 |
ARF like GTPase 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARL3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820
|
|
G |
Arl5a |
ARF like GTPase 5A |
decreases expression |
EXP |
Haloperidol results in decreased expression of ARL5A mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:36,878,461...36,903,362
Ensembl chr 3:36,880,712...36,903,211
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
increases expression |
ISO |
Haloperidol results in increased expression of ARPC4 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
decreases expression |
ISO |
Haloperidol results in decreased expression of ASNS mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Asph |
aspartate-beta-hydroxylase |
increases expression |
ISO |
Haloperidol results in increased expression of ASPH protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1A1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
increases expression |
EXP |
Haloperidol results in increased expression of ATP1B1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp1b2 |
ATPase Na+/K+ transporting subunit beta 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of ATP1B2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:54,318,698...54,324,933
Ensembl chr10:54,318,701...54,324,933
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
increases expression |
EXP |
Haloperidol results in increased expression of ATP1B3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of ATP2A3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp6v1b1 |
ATPase H+ transporting V1 subunit B1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ATP6V1B1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 4:116,223,799...116,242,475
Ensembl chr 4:116,223,799...116,242,475
|
|
G |
Atp6v1b2 |
ATPase H+ transporting V1 subunit B2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ATP6V1B2 mRNA |
CTD |
PMID:16465460 |
|
NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of AXIN2 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of BAX protein Haloperidol results in increased expression of BAX mRNA; Haloperidol results in increased expression of BAX protein |
CTD |
PMID:16462815 PMID:17069804 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat2 |
branched chain amino acid transaminase 2 |
decreases expression |
ISO |
Haloperidol results in decreased expression of BCAT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:96,040,407...96,060,008
Ensembl chr 1:96,042,625...96,060,007
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Haloperidol results in increased expression of BCL2 protein |
CTD |
PMID:17069804 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression decreases expression |
EXP |
EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein] Haloperidol results in increased expression of BCL2L1 protein |
CTD |
PMID:16462815 PMID:17805306 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression decreases expression |
EXP ISO |
BDNF protein inhibits the reaction [Haloperidol results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Haloperidol results in decreased expression of BDNF protein]; Haloperidol inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA] Haloperidol results in increased expression of BDNF mRNA Haloperidol results in increased expression of BDNF protein Haloperidol inhibits the reaction [Cocaine results in decreased expression of BDNF protein] Haloperidol results in decreased expression of BDNF mRNA; Haloperidol results in decreased expression of BDNF protein |
CTD |
PMID:11488957 PMID:12393228 PMID:12478621 PMID:15168214 PMID:17442543 PMID:17805306 PMID:18208916 PMID:20554863 PMID:29182611 More...
|
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bet1l |
Bet1 golgi vesicular membrane trafficking protein-like |
affects expression |
EXP |
Haloperidol affects the expression of BET1L mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040
|
|
G |
Bop1 |
BOP1 ribosomal biogenesis factor |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of BOP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:108,172,062...108,195,875
Ensembl chr 7:108,172,066...108,195,931
|
|
G |
Bptf |
bromodomain PHD finger transcription factor |
decreases expression |
ISO |
Haloperidol results in decreased expression of BPTF mRNA |
CTD |
PMID:14647396 |
|
NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
decreases expression |
EXP ISO |
Haloperidol results in decreased expression of CACNA1A mRNA |
CTD |
PMID:14647396 PMID:16715494 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
affects activity |
EXP |
Haloperidol affects the activity of CALCA protein |
CTD |
PMID:10075105 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calm2 |
calmodulin 2 |
increases expression |
EXP |
Haloperidol results in increased expression of CALM2 mRNA |
CTD |
PMID:19289156 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions increases expression decreases expression |
EXP |
Haloperidol results in decreased expression of and results in decreased phosphorylation of CAMK2A protein Haloperidol results in increased expression of CAMK2A mRNA Haloperidol results in decreased expression of CAMK2A protein |
CTD |
PMID:15860345 PMID:18061412 PMID:19289156 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMK2B mRNA |
CTD |
PMID:15860345 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMK2D mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of CAMK4 protein Haloperidol results in increased expression of CAMK4 mRNA |
CTD |
PMID:15860345 PMID:19289156 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMKK1 protein |
CTD |
PMID:19289156 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CAMKK2 protein |
CTD |
PMID:19289156 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
EXP |
BDNF protein inhibits the reaction [Haloperidol results in increased activity of CASP3 protein]; EPO protein inhibits the reaction [Haloperidol results in increased expression of CASP3 protein] |
CTD |
PMID:15168214 PMID:17805306 PMID:18590723 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases activity decreases expression |
EXP ISO |
Carvedilol inhibits the reaction [Haloperidol results in decreased expression of CAT protein]; Haloperidol results in decreased activity of and results in decreased expression of CAT protein; Zolpidem inhibits the reaction [Haloperidol results in decreased activity of CAT] Haloperidol results in decreased activity of CAT protein Cannabidiol inhibits the reaction [Haloperidol results in decreased activity of CAT protein] |
CTD |
PMID:12010767 PMID:12482469 PMID:16564057 PMID:17513028 PMID:30217539 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbx5 |
chromobox 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CBX5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 7:134,333,165...134,376,102
Ensembl chr 7:134,331,335...134,375,022
|
|
G |
Ccdc121 |
coiled-coil domain containing 121 |
increases expression |
ISO |
Haloperidol results in increased expression of CCDC121 protein |
CTD |
PMID:34122009 |
|
NCBI chr 6:24,970,845...24,973,451
Ensembl chr 6:24,970,833...24,973,478
|
|
G |
Cck |
cholecystokinin |
increases expression |
EXP |
Haloperidol results in increased expression of CCK mRNA |
CTD |
PMID:10974607 |
|
NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CCND1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
EXP |
Haloperidol results in increased expression of CCND3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccnl1 |
cyclin L1 |
increases expression |
EXP |
Haloperidol results in increased expression of CCNL1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CCT8 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression |
EXP |
Haloperidol results in increased expression of CDC42 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
EXP |
Haloperidol results in increased expression of CDK4 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
increases expression |
EXP |
Haloperidol results in increased expression of CDK5 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cfap161 |
cilia and flagella associated protein 161 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CFAP161 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:137,743,783...137,768,685
Ensembl chr 1:137,743,784...137,768,730
|
|
G |
Cfdp1 |
craniofacial development protein 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CFDP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:39,718,313...39,823,824
Ensembl chr19:39,718,347...39,823,824
|
|
G |
Cfl1 |
cofilin 1 |
increases expression |
ISO |
Haloperidol results in increased expression of CFL1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Chl1 |
cell adhesion molecule L1-like |
decreases expression |
ISO |
Haloperidol results in decreased expression of CHL1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 4:136,291,504...136,505,830
Ensembl chr 4:136,291,463...136,503,265
|
|
G |
Chn1 |
chimerin 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CHN1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 3:58,509,822...58,676,462
Ensembl chr 3:58,510,536...58,676,490
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
increases expression |
ISO |
Haloperidol results in increased expression of CHORDC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
affects response to substance |
ISO |
CHRM4 affects the susceptibility to Haloperidol |
CTD |
PMID:21269601 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Cldn11 |
claudin 11 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CLDN11 mRNA |
CTD |
PMID:17177202 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Clta |
clathrin, light chain A |
affects expression |
EXP |
Haloperidol affects the expression of CLTA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:58,244,253...58,263,480
Ensembl chr 5:58,245,442...58,263,472
|
|
G |
Cltb |
clathrin, light chain B |
decreases expression |
EXP |
Haloperidol results in decreased expression of CLTB mRNA |
CTD |
PMID:15860345 |
|
NCBI chr17:10,001,512...10,019,201
Ensembl chr17:10,001,513...10,019,169
|
|
G |
Cmya5 |
cardiomyopathy associated 5 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of CMYA5 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:24,279,520...24,378,253
Ensembl chr 2:24,279,528...24,378,364
|
|
G |
Cnot3 |
CCR4-NOT transcription complex, subunit 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CNOT3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:65,555,924...65,572,167
Ensembl chr 1:65,555,924...65,572,167
|
|
G |
Cnp |
2',3'-cyclic nucleotide 3' phosphodiesterase |
decreases expression |
ISO |
Haloperidol results in decreased expression of CNP mRNA |
CTD |
PMID:17177202 |
|
NCBI chr10:85,511,164...85,517,723
Ensembl chr10:85,511,160...85,517,720
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases methylation |
ISO EXP |
CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK1 protein]]; CNR1 protein affects the reaction [[potassium perchlorate co-treated with 2-mercapto-1-methylimidazole] inhibits the reaction [Haloperidol results in increased phosphorylation of MAPK3 protein]] Haloperidol results in increased methylation of CNR1 promoter Haloperidol inhibits the reaction [Methylazoxymethanol Acetate results in decreased methylation of CNR1 promoter] |
CTD |
PMID:28017790 PMID:30496751 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Coil |
coilin |
increases expression |
EXP |
Haloperidol results in increased expression of COIL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr10:73,789,077...73,810,378
Ensembl chr10:73,789,488...73,810,393
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of COPS3 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
|
|
G |
Cops4 |
COP9 signalosome subunit 4 |
decreases expression |
ISO |
Haloperidol results in decreased expression of COPS4 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:9,078,579...9,108,788
Ensembl chr14:9,078,576...9,108,887
|
|
G |
Cpn1 |
carboxypeptidase N subunit 1 |
increases expression |
EXP |
Haloperidol results in increased expression of CPN1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:242,844,575...242,873,465
Ensembl chr 1:242,844,212...242,873,465
|
|
G |
Cpne3 |
copine 3 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CPNE3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 5:33,014,658...33,063,934
Ensembl chr 5:33,016,307...33,063,934
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases expression increases activity increases phosphorylation |
ISO EXP |
Clozapine inhibits the reaction [Haloperidol results in increased phosphorylation of CREB1 protein] Haloperidol results in increased expression of CREB1 mRNA; Haloperidol results in increased expression of CREB1 protein Amphetamine affects the reaction [Haloperidol results in increased activity of CREB1 protein modified form] |
CTD |
PMID:12125044 PMID:12871586 PMID:26894264 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
decreases expression |
ISO |
Haloperidol results in decreased expression of CRH mRNA |
CTD |
PMID:16205782 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
EXP |
Haloperidol results in decreased expression of CRHBP mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:26,692,403...26,704,710
Ensembl chr 2:26,692,403...26,704,710
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CRY1 mRNA |
CTD |
PMID:27746588 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of CSNK2A1 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Haloperidol results in increased expression of CST3 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Ctnna1 |
catenin alpha 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of CTNNA1 protein |
CTD |
PMID:34122009 |
|
NCBI chr18:26,728,246...26,860,911
Ensembl chr18:26,728,485...26,860,910
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression increases expression multiple interactions |
ISO EXP |
Haloperidol results in decreased expression of CTNNB1 mRNA Haloperidol results in increased expression of CTNNB1 protein DRD2 protein affects the reaction [Haloperidol results in increased expression of CTNNB1 protein] |
CTD |
PMID:16144542 PMID:18797397 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctrl |
chymotrypsin-like |
increases expression |
EXP |
Haloperidol results in increased expression of CTRL mRNA |
CTD |
PMID:16715494 |
|
NCBI chr19:33,827,279...33,829,129
Ensembl chr19:33,827,229...33,833,626
|
|
G |
Ctsk |
cathepsin K |
increases expression |
EXP |
Haloperidol results in increased expression of CTSK mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of CYB5R1 protein |
CTD |
PMID:34122009 |
|
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance |
ISO |
CYP2D6 protein polymorphism affects the susceptibility to Haloperidol |
CTD |
PMID:15538130 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol; Fluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Fluvoxamine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; nefazodone inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; norfluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Trazodone inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol; Fluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; nefazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; norfluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]; Trazodone inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol] |
CTD |
PMID:12584149 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Dcaf6 |
DDB1 and CUL4 associated factor 6 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DCAF6 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr13:77,626,257...77,727,645
Ensembl chr13:77,626,307...77,727,512
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
increases expression |
ISO EXP |
Haloperidol results in increased expression of DCLK1 mRNA |
CTD |
PMID:15860345 PMID:18797397 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Ddx27 |
DEAD-box helicase 27 |
increases expression |
ISO |
Haloperidol results in increased expression of DDX27 protein |
CTD |
PMID:34122009 |
|
NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372
|
|
G |
Ddx46 |
DEAD-box helicase 46 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of DDX46 protein |
CTD |
PMID:34122009 |
|
NCBI chr17:8,942,070...8,988,440
Ensembl chr17:8,944,454...8,988,439
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DDX5 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283
|
|
G |
Dennd10 |
DENN domain containing 10 |
increases expression |
EXP |
Haloperidol results in increased expression of DENND10 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 1:259,950,955...259,974,459
Ensembl chr 1:259,950,866...259,974,455
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
increases expression |
ISO |
Haloperidol results in increased expression of DEPP1 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
decreases expression |
EXP |
Haloperidol results in decreased expression of DGKA mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Dhx36 |
DEAH-box helicase 36 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DHX36 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:146,856,469...146,894,577
Ensembl chr 2:146,856,469...146,894,572
|
|
G |
Dhx38 |
DEAH-box helicase 38 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DHX38 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:37,512,893...37,530,135
Ensembl chr19:37,512,891...37,530,140
|
|
G |
Dlat |
dihydrolipoamide S-acetyltransferase |
decreases expression |
EXP |
Haloperidol results in decreased expression of DLAT mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
|
|
G |
Dlg2 |
discs large MAGUK scaffold protein 2 |
increases expression |
ISO |
Haloperidol results in increased expression of DLG2 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:144,451,653...146,503,949
Ensembl chr 1:144,451,472...146,499,475
|
|
G |
Dnah1 |
dynein, axonemal, heavy chain 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of DNAH1 protein |
CTD |
PMID:34122009 |
|
NCBI chr16:6,455,514...6,517,103
Ensembl chr16:6,456,002...6,518,350
|
|
G |
Dnah3 |
dynein, axonemal, heavy chain 3 |
increases expression |
ISO |
Haloperidol results in increased expression of DNAH3 protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:174,305,929...174,479,490
Ensembl chr 1:174,306,644...174,479,474
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of DNAJB1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
multiple interactions increases expression |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of DNAJB11 protein Haloperidol results in increased expression of DNAJB11 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dpf1 |
double PHD fingers 1 |
increases expression |
ISO |
Haloperidol results in increased expression of DPF1 mRNA |
CTD |
PMID:14647396 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dr1 |
down-regulator of transcription 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of DR1 protein |
CTD |
PMID:34122009 |
|
NCBI chr14:1,458,223...1,469,578
Ensembl chr14:1,458,223...1,469,638
|
|
G |
Drd1 |
dopamine receptor D1 |
affects binding increases expression decreases expression affects activity |
ISO EXP |
Haloperidol binds to DRD1 protein Haloperidol results in increased expression of DRD1 protein Haloperidol results in decreased expression of DRD1 mRNA Haloperidol affects the activity of DRD1 protein |
CTD |
PMID:8750706 PMID:8794996 PMID:12887421 PMID:16983399 PMID:23611293 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
affects binding affects activity multiple interactions increases expression affects response to substance |
ISO EXP |
DRD2 protein binds to Haloperidol; DRD2 protein binds to Haloperidol analog; Haloperidol binds to DRD2 protein Haloperidol affects the activity of DRD2 protein [Haloperidol binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; cyclo(leucylglycine) inhibits the reaction [Haloperidol results in increased expression of DRD2 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Haloperidol results in increased expression of GSK3B protein]; felbamate inhibits the reaction [Haloperidol affects the activity of DRD2 protein]; Haloperidol binds to and results in decreased activity of DRD2 protein; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol inhibits the reaction [iodosulpride binds to DRD2 protein]; Haloperidol inhibits the reaction [Spiperone binds to DRD2 protein]; Haloperidol promotes the reaction [Dopamine binds to DRD2 protein]; zinc chloride inhibits the reaction [Haloperidol binds to DRD2 protein] Haloperidol results in increased expression of DRD2; Haloperidol results in increased expression of DRD2 mRNA; Haloperidol results in increased expression of DRD2 protein Haloperidol binds to DRD2; Haloperidol binds to DRD2 protein; Haloperidol binds to DRD2 protein alternative form [Haloperidol binds to and results in decreased activity of DRD2 protein] which results in decreased susceptibility to Ethanol; [Haloperidol results in increased expression of DRD2 protein] which results in decreased susceptibility to Pentobarbital; Haloperidol binds to and results in decreased activity of DRD2 protein DRD2 affects the susceptibility to Haloperidol; DRD2 protein affects the susceptibility to Haloperidol Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 mRNA]; Thioctic Acid inhibits the reaction [Haloperidol results in increased expression of DRD2 protein] |
CTD |
PMID:1351265 PMID:1361536 PMID:1380082 PMID:2945998 PMID:7845605 PMID:7878047 PMID:8115415 PMID:8200438 PMID:8794996 PMID:9109525 PMID:9808703 PMID:10720636 PMID:10936494 PMID:11172060 PMID:11927170 PMID:11997696 PMID:12191584 PMID:12476322 PMID:14552778 PMID:15716360 PMID:16033416 PMID:16144542 PMID:18295747 PMID:19120057 PMID:20361897 PMID:20730801 PMID:23611293 More...
|
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
affects binding multiple interactions |
ISO EXP |
DRD3 protein binds to Haloperidol analog Haloperidol affects the reaction [Methylazoxymethanol Acetate results in increased expression of DRD3 mRNA] |
CTD |
PMID:14552778 PMID:32360362 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Drd4 |
dopamine receptor D4 |
affects activity affects binding |
ISO EXP |
Haloperidol affects the activity of DRD4 protein Haloperidol binds to Drd4 protein |
CTD RGD |
PMID:23611293 PMID:8078498 |
RGD:7248459 |
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Drp2 |
dystrophin related protein 2 |
increases expression |
EXP |
Haloperidol results in increased expression of DRP2 mRNA alternative form |
CTD |
PMID:16715494 |
|
NCBI chr X:97,607,577...97,658,117
Ensembl chr X:97,607,719...97,655,684
|
|
G |
Dtnbp1 |
dystrobrevin binding protein 1 |
increases response to substance affects response to substance |
ISO |
DTNBP1 gene polymorphism results in increased susceptibility to Haloperidol DTNBP1 protein affects the susceptibility to Haloperidol |
CTD |
PMID:19369910 |
|
NCBI chr17:19,685,218...19,776,668
Ensembl chr17:19,685,215...19,776,661
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of DUSP1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
decreases expression |
EXP |
Haloperidol results in decreased expression of DUSP6 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Dvl3 |
dishevelled segment polarity protein 3 |
multiple interactions increases expression |
EXP |
DRD2 protein affects the reaction [Haloperidol results in increased expression of DVL3 protein] |
CTD |
PMID:16144542 |
|
NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of EEF1G protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Egr1 |
early growth response 1 |
affects expression multiple interactions increases expression |
EXP ISO |
Haloperidol affects the expression of EGR1 protein Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]; OPRM1 protein inhibits the reaction [Haloperidol inhibits the reaction [Methamphetamine results in increased expression of EGR1 mRNA]] Haloperidol results in increased expression of EGR1 mRNA; Haloperidol results in increased expression of EGR1 protein |
CTD |
PMID:12243769 PMID:16452686 PMID:17028028 PMID:17913375 PMID:18208916 PMID:19695244 PMID:20184921 More...
|
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr2 |
early growth response 2 |
affects expression increases expression decreases expression |
ISO EXP |
Haloperidol affects the expression of EGR2 mRNA Haloperidol results in increased expression of EGR2 mRNA Haloperidol results in decreased expression of EGR2 protein |
CTD |
PMID:17028028 PMID:18208916 PMID:19401217 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eif2b5 |
eukaryotic translation initiation factor 2B subunit epsilon |
increases expression |
ISO |
Haloperidol results in increased expression of EIF2B5 protein |
CTD |
PMID:34122009 |
|
NCBI chr11:80,394,433...80,404,468
Ensembl chr11:80,394,433...80,404,419
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of EIF5A protein |
CTD |
PMID:34122009 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
increases phosphorylation multiple interactions |
ISO EXP |
Haloperidol results in increased phosphorylation of ELK1 protein Nifedipine affects the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] SL 327 inhibits the reaction [Haloperidol results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:12871586 PMID:17913375 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Eno1 |
enolase 1 |
increases expression |
EXP |
Haloperidol results in increased expression of ENO1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Epo |
erythropoietin |
multiple interactions |
EXP |
EPO protein inhibits the reaction [Haloperidol results in decreased expression of BCL2L1 protein]; EPO protein inhibits the reaction [Haloperidol results in decreased expression of BDNF protein]; EPO protein inhibits the reaction [Haloperidol results in increased expression of CASP3 protein] |
CTD |
PMID:17805306 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Erap1 |
endoplasmic reticulum aminopeptidase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of ERAP1 protein |
CTD |
PMID:34122009 |
|
NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
EXP |
Haloperidol results in increased expression of and results in increased phosphorylation of ERBB2 protein |
CTD |
PMID:26961615 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
increases expression multiple interactions |
EXP |
Haloperidol results in increased expression of ERBB4 protein Haloperidol results in increased expression of and results in increased phosphorylation of ERBB4 protein |
CTD |
PMID:18184445 PMID:26961615 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ergic1 |
endoplasmic reticulum-golgi intermediate compartment 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of ERGIC1 protein |
CTD |
PMID:34122009 |
|
NCBI chr10:16,531,192...16,626,974
Ensembl chr10:16,531,194...16,626,957
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
Haloperidol results in decreased expression of EZR protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
affects response to substance increases expression |
ISO |
FABP3 affects the susceptibility to Haloperidol Haloperidol results in increased expression of FABP3 protein |
CTD |
PMID:20181611 PMID:34122009 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Haloperidol results in increased expression of FASN mRNA |
CTD |
PMID:16027736 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
haloperidol inhibits the reaction [ethanol increases expression of FGF2 mRNA in dorsal striatum] |
RGD |
PMID:28821667 |
RGD:405855870 |
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of FLT1 protein |
CTD |
PMID:34122009 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fndc4 |
fibronectin type III domain containing 4 |
increases expression |
ISO |
Haloperidol results in increased expression of FNDC4 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases expression |
ISO EXP |
8-Hydroxy-2-(di-n-propylamino)tetralin affects the reaction [Haloperidol results in increased expression of FOS protein]; Dizocilpine Maleate inhibits the reaction [Haloperidol results in increased expression of FOS protein]; ifenprodil inhibits the reaction [Haloperidol results in increased expression of FOS protein]; tandospirone inhibits the reaction [Haloperidol results in increased expression of FOS protein]; traxoprodil mesylate inhibits the reaction [Haloperidol results in increased expression of FOS protein]; WAY 100135 inhibits the reaction [tandospirone inhibits the reaction [Haloperidol results in increased expression of FOS protein]] Haloperidol results in increased expression of FOS mRNA; Haloperidol results in increased expression of FOS protein Haloperidol results in decreased expression of FOS mRNA; Haloperidol results in decreased expression of FOS protein 8-(3-chlorostyryl)caffeine inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of FOS mRNA]; Clozapine affects the reaction [Haloperidol results in increased expression of FOS protein]; Dronabinol promotes the reaction [Haloperidol results in increased expression of FOS protein]; Nifedipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Nimodipine affects the reaction [Haloperidol results in increased expression of FOS protein]; Propranolol inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Scopolamine inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Theophylline inhibits the reaction [Haloperidol results in increased expression of FOS mRNA] |
CTD |
PMID:1393566 PMID:9571656 PMID:9748542 PMID:10199625 PMID:10435392 PMID:11166331 PMID:11409749 PMID:11440804 PMID:11516571 PMID:11602683 PMID:11997696 PMID:12093589 PMID:12125044 PMID:12243769 PMID:12464447 PMID:15120589 PMID:15140647 PMID:17028028 PMID:17913375 PMID:18208916 PMID:18295747 PMID:18521575 PMID:18585397 PMID:18789920 PMID:19352073 PMID:19695244 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO EXP |
Haloperidol results in increased expression of FOSB protein alternative form Haloperidol results in increased expression of FOSB modified form; Haloperidol results in increased expression of FOSB mRNA; Haloperidol results in increased expression of FOSB protein 8-Hydroxy-2-(di-n-propylamino)tetralin inhibits the reaction [Haloperidol results in increased expression of FOSB mRNA] |
CTD |
PMID:8714707 PMID:11180499 PMID:12243769 PMID:15579174 PMID:19695244 PMID:24067299 More...
|
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
Amphetamine affects the reaction [Haloperidol results in increased expression of FOSL1 protein] Haloperidol results in increased expression of FOSL1 mRNA; Haloperidol results in increased expression of FOSL1 protein |
CTD |
PMID:12125044 PMID:18208916 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
EXP |
Haloperidol results in increased expression of FOSL2 mRNA |
CTD |
PMID:12243769 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions increases phosphorylation affects response to substance |
ISO |
FYN gene mutant form inhibits the reaction [Haloperidol results in increased phosphorylation of GRIN2B protein] Haloperidol results in increased phosphorylation of FYN protein FYN protein affects the susceptibility to Haloperidol |
CTD |
PMID:16407246 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
decreases expression |
ISO |
Haloperidol results in decreased expression of GABRA1 mRNA |
CTD |
PMID:18797397 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
increases expression |
EXP |
Haloperidol results in increased expression of GABRB1 mRNA; Haloperidol results in increased expression of GABRB1 protein |
CTD |
PMID:26894264 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
increases expression |
EXP |
Haloperidol results in increased expression of GABRB3 mRNA |
CTD |
PMID:18923069 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions increases expression decreases expression |
EXP |
[Haloperidol co-treated with Fluvoxamine] affects the expression of GAD1 protein Haloperidol results in increased expression of GAD1 mRNA Haloperidol results in decreased expression of GAD1 mRNA; Haloperidol results in decreased expression of GAD1 protein |
CTD |
PMID:12887421 PMID:14519413 PMID:15061247 PMID:15967061 PMID:18923069 PMID:19359144 More...
|
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
decreases expression increases expression |
EXP |
Haloperidol results in decreased expression of GAD2 mRNA; Haloperidol results in decreased expression of GAD2 protein Haloperidol results in increased expression of GAD2 mRNA |
CTD |
PMID:18923069 PMID:19359144 |
|
NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GALNT2 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases expression |
EXP |
Haloperidol results in increased expression of GAPDH mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gda |
guanine deaminase |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in decreased expression of GDA protein |
CTD |
PMID:34122009 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
increases expression |
ISO |
Haloperidol results in increased expression of GDPD3 mRNA |
CTD |
PMID:17175557 |
|
NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression |
ISO |
Haloperidol results in decreased expression of GFAP protein |
CTD |
PMID:34122009 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gimap5 |
GTPase, IMAP family member 5 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GIMAP5 mRNA |
CTD |
PMID:16715494 |
|
NCBI chr 4:77,693,417...77,701,025
Ensembl chr 4:77,687,564...77,703,086
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GJA1 protein |
CTD |
PMID:18585900 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GLO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
EXP |
Haloperidol results in decreased expression of GLUL mRNA |
CTD |
PMID:15860345 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gna12 |
G protein subunit alpha 12 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNA12 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr12:13,805,580...13,886,255
Ensembl chr12:13,805,698...13,886,255
|
|
G |
Gnai1 |
G protein subunit alpha i1 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI1 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 4:16,814,000...16,898,119
Ensembl chr 4:16,814,001...16,896,417
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI2 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAI3 mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
|
|
G |
Gnao1 |
G protein subunit alpha o1 |
multiple interactions |
ISO |
[Cuprizone co-treated with Haloperidol] results in increased expression of GNAO1 protein |
CTD |
PMID:34122009 |
|
NCBI chr19:11,034,874...11,192,531
Ensembl chr19:11,035,956...11,192,493
|
|
G |
Gnas |
GNAS complex locus |
decreases expression |
EXP |
Haloperidol results in decreased expression of GNAS mRNA |
CTD |
PMID:15860345 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
Haloperidol inhibits the reaction [manganese chloride results in increased secretion of GNRH1 protein] |
CTD |
PMID:18603625 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
affects expression multiple interactions |
EXP ISO |
Haloperidol affects the expression of GOT2 mRNA [Cuprizone co-treated with Haloperidol] results in increased expression of GOT2 protein |
CTD |
| |